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Abstract 
Structural and Biochemical Studies of the Human pre-mRNA 3’-end Processing Complex 
Keith Hamilton 
 
 Most eukaryotic pre-mRNAs undergo 3′-end cleavage and polyadenylation prior to their 
export from the nucleus.  A large number of proteins in several complexes participate in this 3′-
end processing, including cleavage and polyadenylation specificity factor (CPSF) in mammals.  
The CPSF can be further divided into two sub-complexes: mPSF (mammalian polyadenylation 
specificity factor) which recognizes the AAUAAA polyadenylation signal (PAS) in the pre- 
mRNA, and mCF (mammalian cleavage factor) which cleaves the RNA.  mPSF consists of 
CPSF160, CPSF30, WDR33, and hFip1.  This thesis shows that AAUAAA PAS is recognized 
with ∼3 nM affinity by the CPSF160–WDR33–CPSF30 ternary complex, while the proteins 
alone or the binary complexes do not bind the PAS with high affinity.  Furthermore, it is shown 
that mutations of residues in CPSF30 that have van der Waals interactions with the bases of the 
PAS lead to a sharp reduction in the affinity.  Finally, variations of the AAUAAA or removing 
the bases downstream also reduce the binding significantly.   
This thesis goes on to characterize the structure of the CPSF30—hFip1 complex, which 
was not observed in the previous EM structures of the mPSF.  It was known that CPSF30 ZF4–
ZF5 recruits the hFip1 subunit of CPSF, although the details of this interaction have not been 
characterized. Here we report the crystal structure of human CPSF30 ZF4–ZF5 in complex with 
residues 161–200 of hFip1 at 1.9 Å.  Unexpectedly, the structure reveals one hFip1 molecule 
binding to each ZF4 and ZF5, with a conserved mode of interaction. Mutagenesis studies 
confirm that the CPSF30–hFip1 complex has 1:2 stoichiometry in vitro. Mutation of each 
binding site in CPSF30 still allows one copy of hFip1 to bind, while mutation of both sites 
abrogates binding. Our fluorescence polarization binding assays show that ZF4 has higher 
affinity for hFip1, with a Kd of 1.8 nM. We also demonstrate that two copies of the catalytic 
module of poly(A) polymerase (PAP) are recruited by the CPSF30–hFip1 complex in vitro, and 
both hFip1 binding sites in CPSF30 can support polyadenylation. 
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1 Introduction to pre-mRNA 3’-end Processing in Humans 
 
1.1 Overview of pre-mRNA 3’-end Processing 
In eukaryotes, most protein-encoding mRNAs are modified at their 3’-end prior to their 
export from the nucleus (Proudfoot 2011; Curinha et al. 2014).  The immature mRNA, known as 
a ‘pre-mRNA’, is acted on by various protein and RNA complexes to produce a mature transcript 
that is capable of being transported to the cytoplasm and being translated into proteins in a 
carefully regulated process.  This process consists of two major modifications to the 3’-end of 
the pre-mRNA: first, the pre-mRNA is cleaved at a specific phosphodiester bond, and second, a 
long (~250 bases in humans) stretch of adenosines is added.  This sequence of events is carefully 
orchestrated, with multiple complexes binding to different elements in the pre-mRNA, providing 
both a tight regulation of cleavage/polyadenylation and the opportunity to select from multiple 
cleavage sites depending on the cellular environment (Zhao et al. 1999; Mandel et al. 2008; Shi 
et al. 2009; Xiang et al. 2014; Sun et al. 2020).  Such multiple cleavage sites lead to many genes 
in the human transcriptome having multiple 3’-untranslated regions (3’-UTRs) when compared 
across tissues and developmental states.  These changes in the 3’-UTRs of many genes have been 
correlated with cell proliferation, differentiation, and tumor progression (Tian and Manley 2016; 
Neve et al. 2017; Gruber and Zavolan 2019).  Understanding the mechanism of how a cell 






1.2 Alternative Polyadenylation (APA) 
About 70% of known human genes have been found to have at least two APA sites, and 
about half with greater than two (Derti et al. 2012; Wang et al. 2018).  Switching between these 
sites can lead to changes in the length of the 3’-UTR of transcribed mRNAs, which has many 
effects on protein expression.  It can change the stability of the mRNA, its localization within the 
cell, or regulation by microRNAs.  The latter can be through directly being silenced, or possibly 
by serving as a “sink” to deplete them in the cell.  Additionally, switching can lead to different 
isoforms, if terminal exon(s) are skipped when a poly(A) site is used prior to them.  Large-scale 
switching of 3’-UTR lengths have been observed in cell differentiation (longer 3’-UTRs) and in 
the induction of pluripotency in somatic cells (shorter 3’-UTRs) (Lianoglou et al. 2013; Xia et al. 
2014). 
The choice of one poly(A) site while ignoring others in the mRNA implies that there is a 
commitment step, wherein once a site is chosen, any other sites are permanently neglected.  
There is nothing to prevent other complexes from still binding to sites upstream of the one 
chosen, so there must be something limiting the cleavage events to one per pre-mRNA molecule 
outside of just binding to the RNA elements.  The most obvious way that the cleavages are 
limited to one per pre-mRNA is that the polymerase (Pol II) is needed to ‘activate’ cleavage, 
since there is one per pre-mRNA transcription (although there might be multiple transcriptions 
per gene at any one time).  Supporting this are its known interactions to the 3’-end processing 
machinery: Ssu72 and Pcf11 bind to the CTD of Pol II, whose phosphorylation state controls the 
steps of transcription (Meinhart and Cramer 2004; Xiang et al. 2010; Hsin and Manley 2012).  
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Another candidate is the splicing machinery, which has also been reported to interact with CFIm, 
sub-complex of the  3’-end RNA processing machinery (Millevoi et al. 2006).  Yet another is the 
5’-cap, since eIF4E has been shown to influence cleavage in some circumstances (Davis et al. 
2019).  But whatever the mechanism, it would not be surprising to find one or more of them as 
an integral but yet unidentified part of the cleavage machinery, the lack of which may explain the 
low cleavage efficiency in vitro.   
 
1.3 Architecture of the Canonical 3’-end Processing Machinery in Mammals 
In mammals, there are four major complexes that contribute to the cleavage and 
polyadenylation reactions, each shown to be separable by classical biochemical techniques for 
many decades (Fig 1.1):  Cleavage and Polyadenylation Specificity Factor (CPSF), Mammalian 
Cleavage Factor I (CFIm), Cleavage Factor II (CFII), and Cleavage Stimulation Factor (CstF) 
(Christofori and Keller 1988; Gilmartin and Nevins 1989; Takagaki et al. 1989).  In addition, 
Poly(A) Polymerase α (PAPα) has long been identified as being responsible for the addition of 
the poly(A) tail, despite having a low apparent affinity for any of these complexes during 






Figure 1.1 Schematic of the human RNA 3’-end processing machinery.  The mPSF 
subcomplex is shown in red, and the mCF is in magenta.  Note: not all observed interactions 
are shown, such as those between CFIm and PAP or Fip1 (from Sun et al., 2020). 
 
1.3.1 CPSF 
 Of the complexes, CPSF is the only one that has been shown to be essential in in vitro 
polyadenylation reactions when combined with PAP (Colgan and Manley 1997; Martin et al. 
2014).  Besides containing the nuclease that cleaves the pre-mRNA, it binds a crucial RNA 
element with high specificity (AAUAAA).  This hexamer, referred to as the Polyadenylation 
Signal (PAS), is found ~20-30 nucleotides upstream of most (~50%) of the cleavage sites used.  
Although some variations are observed (most notably AUUAAA), this sequence is conserved 
throughout metazoans.  The CPSF complex itself consists of two subcomplexes, mammalian 
Polyadenylation Specificity Factor (mPSF) that binds RNA, and mammalian Cleavage Factor 
(mCF) that carries out the cleavage reaction (Martin et al. 2014).   
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The mPSF subcomplex consists of four proteins:  WDR33, which has a conserved N-
terminal region and WD40 domain followed by a long degenerate C-terminal region; CPSF160, 
made up of three intertwined WD40 domains; CPSF30, which has five conserved zinc-fingers 
and a zinc knuckle, separated by a non-conserved and putatively disordered region; and hFip1, a 
long and disordered tethering protein with small segments that are highly conserved.  hFip1 
interacts with mPSF through the zinc-fingers 4-5 of CPSF30, and tethers PAPα and CFIm, in 
addition to binding U-rich RNA regions (Kaufmann et al. 2004; Zhu et al. 2018; Hamilton and 
Tong 2020). 
Concomitantly and in cooperation with the research detailed in this thesis, the structure of 
human mPSF bound to AAUAAA RNA was determined by cryo-EM in our lab (Sun et al. 
2017), and by another lab (Clerici et al. 2018).  It showed that CPSF160 serves as a large 
scaffold onto which the N-terminal regions of both WDR33 (40-420, including the WD40 
domain) and zinc-fingers 1-3 of CPSF30 are arranged in order to bind the RNA hexamer.  hFip1 
and CPSF30 past zinc-finger 3 were not observed and are presumed to be disordered with respect 
to the rest of the complex (Fig 1.2).  The structures showed a tight interaction between the three 
observed proteins, with extensive inter-protein buried surface areas.  The N-terminus of WDR33 
(40-105) first wraps around the RNA, then pokes up in-between two of the β-propellers of 
CPSF160.  Its WD40 domain then caps the bottom of the complex and clamps the other side of 
the RNA.  CPSF30 wraps around CPSF160 with its N-terminus and zinc-finger 1, while zinc-




Figure 1.2 Structure of the mPSF complex bound to PAS RNA. Cartoon representation of 
the cryo-EM structure of mPSF (PDBID 6DNH).  The tri-lobed CPSF160 acts a scaffold 
that holds WDR33 and CPSF30 in place to bind the PAS RNA.  The RNA is held between 
WDR33 and zinc-fingers 2 and 3 of CPSF30, with interactions that specifically recognize 
the AAUAAA hexamer.  The C-terminus (zinc finger 4 to the end) of CPSF30 and hFip1 
were not visible, although present in the complex. 
 
The subcomplex mCF carries out the cleavage of pre-mRNA in the canonical complex as 
well as within a specialized complex that cleaves histone pre-mRNA without mPSF.  In both 
cases it is made of three proteins: Symplekin, CPSF73, and CPSF100 (Martin et al. 2014; Sun et 
al. 2020).  Symplekin is a large structural protein that has several binding partners:  its N-
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terminus binds the Polymerase II CTD through the phosphatase Ssu72, and its long alpha-helical 
C-terminal domains interact with CPSF73 and CstF64 (Xiang et al. 2014).  CPSF73 and 
CPSF100 both have common domains despite having only ~19% sequence identity: a metallo-β-
lactamase domain, β-CASP domain, and C-terminal domains through which the two proteins 
interact with each other and Symplekin (Mandel et al. 2006; Ghazy et al. 2009).  But CPSF100 
differs from CPSF73 in two important respects: first, it has a large, generally poorly conserved 
and flexible insertion within its β-CASP domain that binds CPSF160 and WDR33; and second, 
the metal-binding residues in the nuclease site of the metallo β-lactamase domain are missing.  
This latter observation was used to assign CPSF73 as the nuclease within mCF, despite not 
demonstrating significant cleavage by itself or within the canonical complex using only 
recombinant proteins.  This lack of activity was explained by the structure of CPSF73 (Fig 
1.3A), which showed the metallo-β-lactamase and β-CASP domains closed up upon each other, 
blocking access to the active site (Mandel et al. 2006).  Cryo-EM reconstructions of the whole 
mCF showed a flexible three-lobe configuration (Fig 1.3C), with CPSF73 and CPSF100 only 
interacting though their C-terminal domains with each other and Symplekin, with the domains of 
CPSF73 still in a closed conformation (Zhang et al. 2019).  This closed state with little to no 
cleavage was also observed when the yeast homoloug Ysh1 catalytic module was crystallized 
with a binding partner Mpe1 (Hill et al. 2019).  But in this case, addition of the other factors 
(including the homolog of mPSF) in specific co-expression combinations and in a certain 





Figure 1.3 CPSF73 in a closed and open (RNA-bound) state.  A)  Surface representation 
of the crystal structure of CPSF73 in a non-productive state (PDBID 2I7T).  A sulfate ion is 
bound in the active site (partially visible), but the site is not accessible to RNA.  B)  Surface 
representation of the cryo-EM structure of an active CPSF73 (PDBID 6V4X).  The metallo-
β-lactamase and β-CASP domains are rotated relative to each other to allow an RNA 
molecule to access the active site.  C)  Electron density (gray) of a CPSF73—CPSF100—
Symplekin complex in an inactive state (EMD-20859).  Crystal structures of inactive 
CPSF73 and CPSF100 (green, PDBID 2I7X) are fitted in the density.  The remaining density 
is from Symplekin and the C-terminal domains of CPSF73 and CPSF100.  D)  Surface 
representation of the cryo-EM structure of active CPSF73 in the histone mRNA processing 
complex (PDBID 6V4X).  Interactions of its C-terminal region (pink) with CPSF100 (green) 




It wasn’t until recently that the structure of an active CPSF73 was determined, in the 
context of the histone pre-mRNA processing complex in our lab (Sun et al. 2020).  This showed 
a large rotation of the two domains by ~17°, opening the active site to RNA (Fig 1.3B).  The 
opening seems to be the result of the wedging of Lsm10 --a protein specific to the histone 
complex-- next to the β-CASP domain, along with extensive and newly observed interactions 
with CPSF100 pulling the domains apart (Fig 1.3D).  If the same types of interactions are needed 
to activate CPSF73 within the canonical complex, the proteins that either insert between the two 
domains or hold CPSF73/CPSF100 in a conformation that promotes their interaction have not 
been identified.  It is not clear whether these are completely unidentified, if known proteins 




The complex CFIm binds to the RNA sequence UGUA, which is 40-50 bases upstream of the 
cleavage site in at most half of annotated polyadenylation sites (Brown and Gilmartin 2003; Li et 
al. 2015).  It does not appear to be critical for polyadenylation, but enhances the selection of 
particular PASs when bound to the RNA.  Notably, in many genes the PASs distal from the last 
exon junction are more enriched with UGUAs compared to proximal ones, which has the effect 
of producing shorter 3’-UTRs when CFIm is depleted (Gruber et al. 2012).  The depletion of its 
core component CFIm25 is observed in many cancers, and has been shown to increase 
tumorigenesis by shortening the 3’-UTRs of a significant number of genes, indirectly increasing 
the expression of oncogenes (Masamha et al. 2014; Tan et al. 2018).  Similarly, its suppression 
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has also been shown to be able to enhance the generation of pluripotent stem cells by increasing 
the expression of chromatin regulators (Sommerkamp et al. 2020). 
CFIm25 (also known as Nudt21) is a Nudix-domain protein with the common α-β-α 
Nudix-fold (Coseno et al. 2008; Yang et al. 2010).  But unlike the rest of the family it is not a 
nuclease: an additional α-helix blocks the normal nucleotide-binding cleft and it lacks the 
catalytic site metal-binding residues.  It still binds to RNA, but on a different surface that uses 
this additional α-helix (Fig 1.4C).  The surface creates a new cleft for the UGUA, with multiple 
contacts between the protein and the RNA bases providing specificity while the backbone faces 
the solvent (Fig 1.4B).  Although existing as a dimer, it isn’t clear if binding to two UGUA sites 
at the same time is critical.  By itself it is a symmetric dimer, so any two RNAs bound to the sites 
would run anti-parallel, preventing the use of two binding sites within one pre-mRNA without a 
long spacer to allow the RNA to connect from one site to the other, potentially looping out 
regions of the RNA.  There is speculation that this looping could lead to the skipping of a 
proximal polyadenylation site with UGUA elements on either side, and even preliminary 
evidence that it could be part of the formation of circular RNAs with two UGUAs (Li et al. 
2020). 
The other components of CFIm (CFIm59/68) share a common organization:  an N-
terminal RNA Recognition Module (RRM), followed by a proline-rich region, then an arginine-
serine repeat rich region (RS region) (Fig 1.4A).  Despite its fold, the RRM doesn’t bind to 
nucleotides on its own, but instead caps either end of a CFIm25 dimer, bridging both molecules 
and forming a concave surface that includes the CFIm25 RNA-binding regions (Fig 1.4B) (Yang 
et al. 2011).  The complexes of the RRMs of both CFIm59 and CFIm68 bound to CFIm25 have 
almost identical structures, suggesting the two proteins may act in similar ways (no citation, 
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PDBID 3N9U).  Furthermore, it is not clear if CFIm is formed from both at the same time, as a 
(CFIm25)2—CFIm59—CFIm68 heterotetramer, or whether it is exclusively (CFIm25)2—
(CFIm59/68)2.  Evidence is that they don’t act in the same cellular pathways, with CFIm68 
playing a much more important role in those studies thus far.  Unlike CFIm59, CFIm68 has been 
shown to interact with splicing factors of the SR family, perhaps tying CFIm together with 
splicing (Zhu et al. 2018).  In addition, knockdown of CFIm68 shows very similar APA patterns 
as that of CFIm25 unlike CFIm59 (Li et al. 2015), and also is found with CFIm25 at distal 
poly(A) sites (Brumbaugh et al. 2018).  The mechanism of this poly(A)-site selection is not 
totally clear, but some studies have revealed possibilities. 
It has been shown that both CFIm59 and CFIm68 interact with the RE/D domain of 
hFip1, and that this interaction promotes the use of a UGUA-adjacent cleavage site in vivo (Zhu 
et al. 2018).  Like the other observed effects, this one was much stronger with CFIm68 compared 
to CFIm59.  But although the CFIm68/59—hFip1 interaction was validated using pull-downs in 
vitro, the in vivo evidence is complicated by factors such as the presence of many other RS-
domains in the splicing machinery that is most likely involved in site selection and may serve to 
bridge the components.  It still remains to determine how the CFIm complex plays such a strong 
role in distal site selection, but given its importance in cancer progression and stem-cell 






Figure 1.4 Structure of the human CFIm complex.  A)  Schematic of the domain 
organization of the proteins in human CFIm.  B) Structure of the human CFIm25—
CFIm68—RNA complex (PDBID 3Q2T).  The 3’ ends of the UGUA RNA are in proximity 
to each other, showing the necessity of looping to reverse the direction of the RNA between 
binding sites, if bound to a single strand.  The RRM of CFIm59 binds in an identical fashion 
as that of CFIm68.  C) One CFIm25 monomer overlaid with the Nudix-domain protein 
Nudt16 (yellow, PDBID 6X7V).  The non-Nudix domain extensions in CFIm25 that create 







PAPα was identified as the main polymerase that adds the poly(A) tail during canonical 3’-end 
processing decades ago (Christofori and Keller 1988; Wahle et al. 1991).  When CPSF was 
purified from cell-culture nuclear extract, only a small fraction of PAPα was bound, with most 
existing as free protein.  But only the fraction bound to CPSF was competent to polyadenylate 
RNAs containing an AAUAAA site in the presence of Mg+2; it was only when the free protein 
was incubated with Mn+2 that the RNA was polyadenylated at a high level (Takagaki et al. 1988; 
Wahle 1991).  Kinetic data explained why, and suggested a mechanism for PAPα activation by 
CPSF binding.  It was shown in the presence of Mn+2, PAPα binds to the RNA primer ~30-100x 
stronger than in the presence of Mg+2, despite both having about the same Vmax(Martin et al. 
2004).  This led to the supposition that since PAPα bound to the presumed cellular cofactor of 
Mg+2 doesn’t interact strongly with the RNA primer by itself, it needs to be brought into contact 
with it by CPSF.  The fact that only a small fraction of PAPα was bound also suggests that it 
either binds very weakly to CPSF or there is some post-translational regulation of the binding.  If 
it is the former, the very weak CPSF binding must somehow compensate for the weak RNA 




Figure 1.5 Structures of yeast and human Poly(A) Polymerases.  A)  MUSCLE alignment of 
PAP from various model organisms (Edgar 2004).  Highly conserved residues are in red, and 
gray are not conserved.  Yeast, fruit fly, and nematode are missing the C-terminal region present 
in the vertebrates.  B)  Structure of the bovine PAPα (catalytic to RNA-binding domains, 
PDBID 1Q79).  ATP and a magnesium ion are bound in the active site.  Human PAPα is almost 
completely identical to this portion of bovine PAPα.  B)  S. cerevisiae PAP bound to poly(A) 
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RNA (PDBID 3C66).  It can be seen that the structure is almost identical, save for some extra 
helices in the RNA-binding domain (α2-α4).  The catalytic and RNA-binding domains clamp 
onto the RNA to bring its 3’ close to the active site and the ATP.  C)  S. cerevisiae Fip1 bound 
to PAP (PDBID 3C66), aligned with the bovine RNA-binding domain (RBD) from (B).  The 
equivalent to the yeast helix α5 in the bovine RBD clashes with the Fip1, and may move when 
bound to the bovine Fip1 (see chapter 3 for a more complete discussion). 
 
 PAPα has a well-conserved N-terminal region that carries out the polyadenylation 
reaction, followed by a variable region of ~200 amino acids, then a short ~40 residue highly-
conserved stretch at the C-terminus (Fig 1.5A).  The N-terminal catalytic region is soluble when 
expressed in E. coli, and can carry out polyadenylation reactions in solution (Wahle et al. 1991).  
The crystal structure of this region has been solved, and was shown to be very similar to the 
structure of yeast PAPα (Fig 1.5B,C), despite a low sequence identity (~36%) (Bard et al. 2000; 
Martin 2000).  Both have three annotated domains: a catalytic domain (residues 53-173), an 
RNA-binding domain (residues 353-498), and a central domain (r. 20-52, 174-352) flanked by 
both.  Comparison across multiple crystal structures (both mammalian and yeast) have 
demonstrated that the catalytic and RNA-binding domains are flexible with regard to the central 
domain, with the catalytic domain opening and closing on the ATP substrate.  The RNA-binding 
domain (which interacts with and guides the poly(A) RNA primer to the active site) only has 
limited contact with the central domain, so the multiple conformations observed might represent 
an inherent flexibility between the two in solution.   
 The link between CPSF and PAPα is hFip1, which binds to the RNA-binding domain of 
PAPα in both mammals and yeast (Barabino et al. 2000; Kaufmann et al. 2004).  The structure of 
yeast PAPα—Fip1 complex was solved by X-ray crystallography (Fig 1.5D), and although the 
binding site is present on mammalian PAPα, the region of human hFip1 that binds PAPα is not 
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easily found by comparing it to the yeast due to the divergence between the sequences (Meinke 
et al. 2008).  The best evidence is a pull-down study which showed that residues 1-111 of human 
hFip1 could interact to some extent with PAPα (Kaufmann et al. 2004).  Alignment between a 
slightly longer human segment and the yeast Fip1 found in the structure show a weak alignment 
between residues 92-132, with insertions in regions not bound to PAPα in yeast. 
 Other proteins have been shown to bind to the C-terminal region of PAPα, which the 
yeast polymerase lacks.  Residues 81-160 of CFIm25 have been shown to interact with residues 
677-745 of PAPα, which would place the interaction on the opposite surface of CFIm25 as the 
RNA binding site (Kim and Lee 2001; Dettwiler et al. 2004).  It is not known what role this 
plays in polyadenylation, if any.  This same residue range of PAPα has also been shown to bind 
to the pol(A) binding protein that is present in the nucleus (PABPN1) in the presence of poly(A) 
with a length of at least 10 nucleotides (Kerwitz et al. 2003).  This association stabilizes the 
interaction of PAPα with the RNA, accelerates the polyadenylation reaction, and limits its length 
to ~250 bases (Kühn et al. 2009; Kühn et al. 2017).  It is hypothesized that PABPN1 acts a kind 




Cleavage stimulation Factor (CstF) is composed of two copies of each of three proteins to 
form a hexameric assembly: CstF77, CstF50, and CstF64 (Yang et al. 2018).  The complex 
appears to be critical for the cleavage of the pre-mRNA, but not for the subsequent 
polyadenylation (Takagaki et al. 1989; Martin et al. 2014).  CstF binds to U and G/U-rich 
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elements in the pre-mRNA downstream of the cleavage site through the RNA-recognition motif 
(RRM) domain of each CstF64 monomer (Pérez Cañadillas and Varani 2003; Salisbury et al. 
2006).  This binding can influence the selection of polyadenylation sites, as shown by depleting 
CstF64 and its variant CstF64τ.  Doing so shifts the trend of site selection from proximal to distal 
ones, and also promotes the use of non-canonical sites (Yao et al. 2012; Hwang et al. 2016). 
A structure of CstF77 bound to mPSF shows that it interacts with mPSF through both 
CPSF160 and WDR33 (Zhang et al. 2019).  Only one copy of mPSF was observed despite there 
being no apparent clashes if two copies were bound to the CstF77 dimer.  CstF is also connected 
to mCF, though an interaction between CstF64 and Symplekin (Yao et al. 2013). 
 
1.3.5 CFII 
 Human Cleavage Factor II (CFIIm) is much less extensively characterized complex, in 
comparison to the others in the pre-mRNA 3’-end processing complex.  It consists of two 
proteins in a heterodimeric complex: Pcf11 and Clp1, the former of which appears to bind to G-
rich RNA downstream of the CstF-binding region (Schäfer et al. 2018) and also the CTD of PolII 
(Meinhart and Cramer 2004).  Pcf11 also has been seen to a critical regulator of alternative 
polyadenylation, and its down-regulation is associated with tumerigenesis (Ogorodnikov et al. 
2018).  Human Clp1 is a kinase whose activity is necessary for the maturation of tRNAs (Karaca 
et al. 2014), but apparently not for pre-mRNA 3’-end processing (Hanada et al. 2013).  In 





1.4 Thesis overview 
Over the course of this thesis, I will detail my investigations into the structure and 
function of parts of the human 3’-end RNA processing complex.  The second chapter deals with 
testing the RNA-binding characteristics of mPSF and its components.  I tested both CPSF30 and 
WDR33 for their ability to bind with specificity to the AAUAAA RNA hexamer, and found that 
although they bind, they can’t distinguish it from a mutant sequence.  I then expressed a complex 
consisting of CPSF30—WDR33—CPSF160, and showed that it can both bind the hexamer and 
distinguish it from a mutant RNA.  Following this, I carried out preliminary EM studies on this 
complex, which were taken up and completed by Yadong Sun and Yixiao Zhang when they 
solved the structure using cryo-EM.  I then used this structure to guide the quantitative 
measurement of binding between wild-type mPSF, mutant mPSF, its components and various 
lengths and sequences of RNA. 
 In the third chapter, I discuss the structure and behavior of the CPSF30—hFip1 complex.  
I solved the structure of this complex using X-ray crystallography, and observed an unexpected 
1:2 stoichiometry.  I then validated that two hFip1s bind to one CPSF30 by mutating the latter, 
disrupting each or both of the hFip1 binding sites.  Using these, I demonstrated that the expected 
number of hFip1s bind to the wild-type and mutant CPSF30s in solution.  I followed this with a 
quantification of the binding constants.  I then confirmed that hFip1 bound to each of the single 
mutants can recruit PAPα in order to carry out polyadenylation in vitro. 





2 RNA Binding Studies of mPSF and its Components 
 
2.1 Introduction 
For many years it was believed that CPSF160 was the protein responsible for binding to 
the AAUAAA polyadenylation signal (PAS), despite showing low RNA binding and negligible to 
no preference for the sequence (Keller et al. 1991; Murthy and Manley 1995).  In 2009 a mass-
spectrometry based survey of peptides pulled down from HeLa nuclear extract using MS2-tagged 
viral pre-mRNAs as the bait found many new partners, including a strong signal from an 
uncharacterized protein WDR33 (Shi et al. 2009).  This new component of the CPSF machinery 
was most likely missed because its molecular weight was very close to that of CPSF160, so the 
two proteins would co-migrate on the SDS-PAGE gels used to identify the constituent parts of 
CPSF up to that point.  Further work clearly found that when expressed with CPSF160 this new 
protein and the previously known CPSF30 were the actual binding partners of the AAUAAA 
hexamer (Chan et al. 2014; Martin et al. 2014).  Through intentional and serendipitous truncations 
(WDR33 was cleaved during purifications by a peptidase) the regions of each protein needed to 
bind the PAS were determined.  WDR33 required the first ~450 residues, while zinc-fingers 2-3 
(and possibly the zinc-knuckle) were most important for CPSF30.  It wasn’t understood whether 
both proteins actually bound the RNA, or if one played a role in bridging the other to CPSF160.   
WDR33 is the mammalian homolog of Pfs2p, a yeast protein previously shown to be 
critical for 3’-end cleavage and polyadenylation (Ohnacker 2000).   It has a conserved WD40 
repeat following a somewhat conserved ~100 residue N-terminal end, then a long poorly-
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conserved C-terminal region containing a collagen-like domain which is not present in the yeast 
homolog (Fig 2.1).  CPSF30 is composed of a conserved N-terminus and five consecutive zinc-
fingers (ZF1-5), followed by a less-well conserved region, then a conserved zinc-knuckle (ZK) 
(Fig 2.4).  Zinc-fingers 2-3 (ZF2-3) of CPSF30 had previously been shown to interact with the so-
called “effector-domain” of the NS1 protein from the influenza A/Udorn/72 virus (Das et al. 2008).  
If these were indeed the region crucial for PAS binding, it would explain the virus’ ability to so 
effectively shut down endogenous 3’-end processing. 
I set out to test each protein to see if either could bind the PAS while also discriminating it 
from mutant RNA sequences, and if they could, how.  I first expressed CPSF30 and WDR33 
separately, and showed that although they did bind RNA, they could not distinguish between the 
wild-type PAS and a mutant.  I then expressed and purified a complex of CPSF30, WDR33, and 
CPSF160, and showed that it could bind the two RNA sequences with different affinities.  This 
was used to carry out preliminary EM studies.  I finally used the structure of mPSF as determined 
by Yadong Sun and Yixiao Zhang to direct quantitative studies of RNA binding to mPSF (Sun et 
al. 2017). 
 
2.2 Experimental Procedures 
2.2.1 Protein expression and purification 
Various segments of human CPSF30 (residues 62-244 or 1-244) were cloned into a pET28a 
vector modified to be ampicillin resistant with an N-terminal His-tagged yeast SMT3.  Isoform 2 
of CPSF30 was used, where residues 191-215 are missing. With this isoform, full-length CPSF30 
has 244 residues. hFip1 (residues 159-200) was cloned into a pET28a vector, in-frame with N-
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terminal His-tagged yeast SMT3 as a solubility tag. Mutations and deletions of CPSF30 were 
carried out using the QuikChange protocol (Agilent). 
Truncations of human WDR33 were cloned into the MCS1 of pFL, in-frame with either an 
N-terminal His-tag or a TEV-cleavable His-tagged MBP.  CPSF30 was cloned into the same pFL, 
into the MCS2, with no tag.  CPSF160 was also cloned into the MCS1 site of either a separate pFL 
or pUCDM, also without any tags.  The CPSF160-containing pUCDM plasmid was inserted into 
the WDR33 and CPSF30-containing pFL plasmid using the Cre/Lox system.  The pFL plasmids 
were inserted into the bacmid using the E. coli host strain DH10Bac, which was used to transfect 
Sf9 cells. 
All E. coli expressions were carried out in LB media using E. coli BL21(DE3) cells. Each 
was induced with 0.5 mM IPTG and incubated at 17 °C for 18 h prior to harvesting by 
centrifugation. The expressions using the baculovirus system were carried out in Hi5 cells for 48h.  
For both, the resulting cell pellets were flash-frozen and stored at –80 °C until use.  
The CPSF160–WDR33–CPSF30 and the CPSF160–WDR33 complexes were purified 
following the same protocol. The insect cells were lysed by sonication in a buffer containing 50 
mM Tris (pH 8.0), 500 mM NaCl, 30 mM imidazole, 10 mM beta-mercaptoethanol, and one 
SIGMAFAST protease inhibitor cocktail tablet.  The lysate was mixed with 2 mL Ni-NTA beads 
(Qiagen), washed with 15 mL buffer containing 2 M NaCl to remove bound nucleic acids, then 
the protein was eluted with 5 mL buffer containing 250 mM imidazole. 1 mg TEV protease was 
added, and the sample was incubated overnight at 4°C. It was then run over a Superdex200 16/60 




The E. coli expressed Fip1/CPSF30 complexes were lysed by sonication in a buffer 
containing 50mM Tris (pH 7.5), 500 mM NaCl, 30 mM imidazole, 10 mM beta-mercaptoethanol, 
100 µM ZnSO4, and 2 mM PMSF. The lysate was incubated with 5 mL Ni-NTA, washed with 20 
mL buffer containing 2M NaCl to remove bound nucleotides, then eluted with 10 mL buffer 
containing 250 mM imidazole, 100 µM ZnSO4, and 500 mM NaCl. To cleave, 100 µg UlpI 
protease was added, and the sample was incubated at 4°C overnight. It was then incubated again 
with 5mL Ni-NTA to remove the His-tagged SUMO, and the flow-though was run over a Superdex 
200 16/60 column using a buffer containing 20 mM Tris (pH 7.5), 500 mM NaCl, 100 µM ZnSO4, 
and 10 mM DTT.  The CPSF30 alone samples were purified in the same manner, but with the 
addition of 50mM arginine to prevent precipitation. 
For Fip1, the cells were lysed by sonication in a buffer containing 50mM Tris (pH 7.5), 200 mM 
NaCl, 30 mM imidazole, 10 mM beta-mercaptoethanol, and 2 mM PMSF. The lysate was 
incubated with 5 mL Ni-NTA, washed with 20 mL buffer, then Fip1 was eluted with 10 mL buffer 
containing 250 mM imidazole and 100 mM NaCl. To cleave, 100 µg UlpI protease was added, and 
the sample was incubated at 4°C overnight. It was then purified further using a 5 mL Fastflow 
MonoQ column followed by a Superdex 200 16/60 column using a buffer containing 20 mM Tris 
(pH 7.5), 100 mM NaCl, and 10 mM DTT. 
 
2.2.2 Electrophoretic Mobility Shift Assays (EMSA) 
All samples were incubated with FAM-labeled RNA on ice in buffer containing 20 mM 
Tris 7.5, 200 mM NaCl, 5 mM DTT, 0.01% NP40, and 5% glycerol.  CPSF30 samples had 50 mM 
arginine added.  The mPSF complex samples were run on a 0.5% agarose/3% polyacrylamide gels 
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using TBE running buffer.  The rest were run on 4-20% Bis-Tris gels using tricine running buffer 
(Hellman and Fried 2007).  The gels were visualized using a Typhoon FLA 7000 (GE Healthcare). 
 
2.2.3 Analytical gel filtration experiments 
50 µL of each sample was mixed and incubated on ice for 1 h, and then run on a Superose 
12 10/300 column (GE Healthcare). The buffer contained 20 mM Tris (pH 7.5), 500 mM NaCl, 
50mM arginine, and 10 mM DTT. The molecular weight of the eluted samples was calculated 
using a linear equation calibrated with a set of protein standards (BioRad). 
 
2.2.4 NMR of CPSF30 and RNA 
CPSF30 (62-244) was expressed in M9 minimal media supplemented with 15NH4, and 
purified in the same manner as previous samples. It was then exchanged into a buffer composed 
of 20 mM Tris 7.5, 200 mM NaCl, 50 mM Arg, 20 µM ZnSO4, 10 mM DTT, and concentrated to 
three aliquots of 150 µL, at a concentration of 120 µM (2.7 mg/mL).  Then 22.5 µL of either ddH2O 
(apo sample) or 1 mM RNA (either 17-mer PAS or RPL32) was added to the sample.  They were 
then re-concentrated to 150 µL, to bring the RNA concentration to 150 µM.  The samples were 
added to a 3mm Shigemi NMR tube along with 5% D2O for the magnetic field lock and 20 µM 
DSS for an internal chemical shift reference.  Spectra were acquired on a Bruker AVANCE III HD 
700 MHz spectrometer equipped with a cryoprobe at 20°C at the Advanced Science Research 




2.2.5 Fluorescence polarization binding assays.  
The assays were performed using a Neo2S plate reader (Biotek). The buffer for all the 
assays contained 20 mM Tris (pH 8.0), 150 mM NaCl, 10 mM DTT, 0.01% NP-40, 100 nM BSA. 
A 17-mer oligonucleotide that included a polyadenylation site and the surrounding bases from the 
SV40 virus and a 6-carboxyfluorescein (6-FAM) 5’-end label was used as the probe at a 
concentration of 1 nM in all competition-binding experiments. For assays that involved titration 
with CPSF30, various molar ratios of CPSF30–Fip1 were added to CPSF160–WDR33 and the 
mixture was allowed to incubate on ice for 1 h.  Where indicated, the buffer contained 1 µM Fip1-
159-200, as it was observed to prevent oligomerization of the tertiary complex at high 
concentrations (data not shown). Oligonucleotides were purchases from IDT. Both the direct 
binding and competition experiments were fit to analytical equations (Wang 1995; Lundblad et al. 
1996) using the optimize package from SciPy version 1.1.0 (Oliphant 2007).  Statistical 
significance was tested by performing an F-test using both the global fit and individual fits of pairs 
of curves, with the stats package from SciPy version 1.1.0.  All titration experiments were carried 






2.3.1 WDR33 Expression and Purification 
Various truncations were cloned into pET vectors and expressed with either C or N-
terminal His-tags in BL21(DE3) E. coli, but despite high expression all the constructs were 
insoluble.  Adding a TEV-protease cleavable His-tagged MBP to the N-terminus of each construct 
did produce soluble protein, but it all proved to be aggregated when run on a gel filtration column.  
It wasn’t until the protein was expressed using the Multi-Bac system (Fitzgerald et al. 2006) that 
small amounts of somewhat pure and monomeric WDR33 were purified.  Adding the MBP tag to 
each baculo-virus expressed construct helped somewhat, but the yield still remained small and 
impure.  The best truncations spanned just the WD40 domain (105-425), although longer 
constructs were still viable (1-572), and especially 13-545 (Fig 2.2).  Since this last construct 
covered the region observed to bind RNA, it was determined to be long enough to characterize the 
RNA interaction.   
 
Figure 2.1  Multiple sequence alignments of WDR33.  WDR33 or its equivalent from 
several model organisms are aligned (red: identical, light red: similar, grey: not similar) 
using MUSCLE (Edgar 2004).  Positions of primers used to clone the WDR33 constructs 






Figure 2.2  Purification of the N-terminal WD40 domain of WDR33 shows it is a monomer 
in solution.  280 nm absorption profile and SDS-PAGE from gel filtration of WDR33 (13-
545) with a N-terminal Histag.  The estimated molecular weight from the retention volume 
is 64.0 kDa (actual 65.1 kDa). 
 
2.3.2 WDR33 EMSA 
Titrations of WDR33-13-545 were incubated with 0.2 µM 17mer-RNA labeled with 5-
FAM.  The RNA sequences were from the SV40 late-stage polyadenylation site, with either the 
wild-type AAUAAA PAS or a mutant AACAAA which was shown to bind weakly to the mPSF 
complex, labeled with a fluorescent tag on the 5’ end.  They were then run on a native Bis-Tris gel 
to resolve the complex formation, and imaged with a phosphor-imager (Fig 2.3).  The results 
showed binding in three distinct bands: presumably different stoichiometries of WDR33—RNA.  
The surprising part was that both the WT and the mutant titrations looked almost exactly the same, 
indicating that WDR33 cannot discriminate between them.  This led to the conclusion that WDR33 
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does not bind alone to the PAS in CPSF.  It either serves to interact with the surrounding RNA 
while another subunit binds specifically the PAS, or itself only discriminate when other subunits 
join to form a binding interface. 
 
 
Figure 2.3 EMSA of WDR33 with FAM-labeled RNA shows a lack of specific binding.  
Both wild-type of mutant RNA bind to WDR33 with equal affinity, indicating that WDR33 









2.3.3 CPSF30 Expression and Purification 
 Various truncations of CPSF30 were cloned into an ampicillin-resistant pET28a vector 
with N-terminal His-tagged yeast SMT3 as a solubility tag.  Small-scale expression showed that 
while a construct that spanned just ZF2-3 was very soluble, extending towards either end (1-ZF3 
or ZF2-ZK) significantly decreased the solubility but still produced some usable protein.  The full-
length protein (1-ZK) was barely soluble.  After testing various constructs from expression through 
to gel filtration, the construct that spanned zinc-finger 2 to the end (ZF2-ZK) proved to be the 
longest construct that was monomeric, reasonably stable, and contained all regions thought to be 
important for RNA binding (Fig 2.5).   
 
 
Figure 2.4  Multiple-sequence alignment of CPSF30.  CPSF30 or its equivalent from 
various model organisms are aligned using MUSCLE (red: identical, light red: similar, grey: 
not similar). Positions of primers used to clone the CPSF30 constructs are shown in green.  
Domains annotated on human CPSF30 are shown above the alignment. It can be seen that 
zinc-fingers 2 to 5 are highly conserved, with the exception of an insertion in zinc-finger 4 
of C. elegans.   
 
When expressed, all the soluble constructs contained large amounts of iron instead of zinc, 
as evidenced by their bright red color.  Supplementing the culture with 100 µM ZnSO4 prior to 
expression did little to lessen the problem, and only served to limit the growth of the bacteria.  It 
is assumed that the large amount of a multiple zinc-finger-containing protein expressed 
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overwhelmed the normally small amount of zinc in the E. coli cytoplasm at homeostasis.  It was 
found that supplementing the purification buffers throughout the purification with 100 µM ZnSO4 
resulted in the removal of nearly all the iron, with the residual red-colored protein separated during 
ion-exchange and gel filtration. 
 The construct that spanned zinc-finger 2 to the end (referred to from now on as CPSF30-
ZF2-ZK) eluted from the Ni-NTA column along with a large amount of nucleic acid (OD260/280 
~ 1.7), so it was run over a heparin column prior to polishing with gel filtration.  Additionally, it 
was found to heavily precipitate during concentration without the addition of 50mM arginine to 
the buffer to stabilize it.  With these modifications, the protein was found to be stable and 
monomeric up to ~3 mg/mL (~150 µM). 
 
 
Figure 2.5 Gel-filtration shows that CPSF30-ZF2-ZK is a monomer. Gel-filtration of 
CPSF30-ZF2-ZK indicates that the protein is a monomer with an estimated molecular weight 
of 18.2 kDa (actual = 21.0 kDa), as shown in the 280 nm trace on the left. The band arising 
from the degradation of CPSF30 is visible in the SDS-PAGE gel (right), and this band 




 The preparation of purified protein spanned over 2 days (including Ni-NTA purification, 
SUMO cleavage, heparin, and gel filtration) to allow for complete exchange with Zn+2, and during 
that time a significant and sharp degradation band appeared on SDS-PAGE gels, indicating that 
CPSF30-ZF2-ZK was cleaved at a specific position within the non-conserved region between ZF5 
and the ZK (Fig 2.5).  Since this wasn’t slowed by protease inhibitors and may have complicated 
biochemical characterizations, a series of deletions were made.  It was found that the third deletion 
tried (residues 192-200, referred to as CPSF30-Δ3-ZF2-ZK) eliminated the degradation issue (Fig 
2.6).  It also allowed the small amounts of the construct that included ZF1 to be purified, since 
more of the protein remained intact after gel filtration. 
 
 
Figure 2.6 Deletion 3 stops the degradation of CPSF30.  A)  MUSCLE alignment of 
CPSF30, with the regions deleted indicated.  Orange squiggles indicate where the is an 
insertion compared to the human sequence.  B)  Gel-filtration results of CPSF30-ZF2-ZK 
deletion 3.  To test for degradation, the samples for SDS-PAGE were incubated at room-




2.3.4 CPSF30 Crystallization Trials 
The construct CPSF30-ZF2-ZK was purified and concentrated to 3 mg/mL and used to set 
up trays for crystallization screens using a mosquito robot using 576 conditions.  Slightly less than 
half of the drops had precipitation, but there were no crystals seen even after a few months of 
incubation at 20°C.  It was thought that perhaps the zinc-fingers are flexible relative to each other 
and would therefore be difficult to crystallize. 
 
2.3.5 Analytical Gel Filtration of CPSF30 with RNA  
To characterize the binding of CPSF30 with RNA, 150uM CPSF30-Δ3-ZF2-ZK was 
mixed with 200uM unlabeled 17mer SLV40 PAS RNA or the equivalent amount of buffer.  After 
incubating on ice, the mixtures were run over a Superose-12 10/30 column using an AKTA system 
(Fig 2.7).  With the addition of a PAS-containing RNA, the protein was shifted to a higher retention 
time, increasing the calculated molecular weight by 5.7 kDa, the mass the RNA (calculated Δ of 





Figure 2.7 CPSF30 binds to PAS RNA in a 1:1 complex.  Analytical gel-filtration of 
CPSF30 (ZF2-ZK) mixed with PAS RNA shows that the addition of the RNA shifts the 
retention volume to that of a 1:1 complex.  The SDS-PAGE of the two gel-filtration assays 
is shown on the left, and the 280 nm traces are on the right.  CPSF30 alone is in blue, and 
with RNA is in red. 
 
2.3.6 CPSF30 EMSA 
EMSA with various CPSF30 constructs was carried out using the same protocol as with 
WDR33.  Various constructs of CPSF30 were used to test whether and where on the protein RNA 
binding and PAS discrimination occurs (Fig 2.8).  The shortest of those tested (CPSF30-ZF2-ZF3) 
spanned the region determined to be most critical for PAS binding, so it was assumed that it would 
bind to RNA on its own.  But surprisingly it did not, even at 5 µM.  Trying a longer construct that 
ended just before the zinc-knuckle (CPSF30-ZF2-ZF5) yielded some binding, but like WDR33 it 
showed no discrimination between the WT and mutant PASs.  Extending the construct to include 
the terminal zinc-knuckle did not improve the situation, and the results were analogous but with 
slightly tighter binding.  To test a construct that included zinc-finger 1, the internal deletion was 
employed (CPSF30-Δ3-ZF1-ZK), which necessitated comparing CPSF30-Δ3-ZF2-ZK to the same 
construct without the deletion.  This was done, and all looked similar, indicating that zinc-finger 
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1 made no difference to binding.  The unrelated RNA RPL32 was again used with CPSF30-Δ3-
ZF2-ZK, and it had the same binding as both WT and mutant PASs.  
 
 
Figure 2.8 EMSA of various CPSF30 truncations with FAM-labeled RNA shows non-
specific binding.  Various truncations of CPSF30 were incubated with either wild-type or 
mutant FAM-labeled PAS RNA.  It can be seen that the construct spanning zinc-fingers 2 to 
5 has some affinity to RNA.  Extending the construct to include the zinc-knuckle or zinc-






2.3.7 NMR of CPSF30 with RNA 
Given the lack of success crystallizing CPSF30-ZF2-ZK, the possibility of using NMR to 
determine the structure and RNA binding mode was tested.  Since this construct is ~20 kDa, it 
would likely be amenable to this method without extensive labeling strategies, as long as it was 
stable, well-folded, and monomeric (Cavanagh et al. 2007a).  In order to test how it behaved --and 
how useful NMR would be-- it was decided to label the protein using 15N, and perform NH-HSQC 
(heteronuclear single-quantum coherence) experiments.  These use the inherent sensitivity of the 
100% abundance 1H nuclei to transfer magnetization through-bond J-coupling to the relatively 
insensitive 15N nuclei, then back again to detect on the 1H (Cavanagh et al. 2007b).  As the 
magnetization spends time on the 15N nuclei, it processes sinusoidally at the frequency of that 
nuclei’s chemical shift.  By varying the time spent on the 15N-nuclei between different acquisitions, 
an indirect sinusoidal plot can be traced for each, modified by an exponential decay due to 
“relaxation” of the magnetization of the 15N.  After the time spent on the 15N nuclei, the 
magnetization is transferred back to the 1H, and the signal is acquired.  Like the 15N signals, each 
is modified by an exponential due to relaxation, so that the final shape of each peak is Lorentzian.   
When a 2-dimensional Fourier-transform is carried out on this set of acquisitions, a 2D plot is 
obtained with a peak corresponding to each N-H pair.  The relaxation that modifies these peaks is 
from the bulk magnetization of the nuclei either returning to the ground state by transferring 
magnetization to surrounding nuclei, or decoherence due to varying magnetic fields, from either 
molecular tumbling, internal movement, or exchange between states with different chemical shifts.  
A nucleus which has a short relaxation time produces a broad peak, as the shorter time the signal 
is there the less precise one can be about the frequency, and the more the frequencies are smeared 
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when a Fourier transform is done.  Therefore, the comparative shape of a peak can tell one 
something about the possible dynamics of different parts of a sample. 
These types of experiments have been shown to be very informative for deciding whether 
a sample was likely to produce good enough spectra for determining its 3D structure.  They also 
give clues about the secondary structure, which may inform further truncations or internal 
deletions.  In addition, they could also be used to compare the protein with and without RNA, since 
peaks in the NH spectrum corresponding to residues interacting with the substrate would shift, 
split, or broaden, depending on the strength of the interactions (Palmer et al. 2001).  It would not 
be possible to identify which residues shifted (besides informed guesses about the type) until the 
construct was expressed with both 13C and 15N labeling, and the appropriate 3D-experiments were 
carried out to allow the assignments of each resonance frequency to a nucleus (Cavanagh et al. 
2007c).  But 13C-labeled media is much more expensive than 15N-labeled, so this first evaluation 
step is critical. 
The protein was expressed in M9 minimal media supplemented with 15NH4, and purified 
in the same manner as previous samples, and concentrated to 120 µM (2.7 mg/mL).  All the NMR 
spectra were acquired From the 1D 1H experiments run initially, it was determined that acquiring 
the NH-HSQC for ~8h (200 indirect points, 128 scans each) would accumulate enough signal for 
a decent signal/noise ratio. 
The peaks in the resulting spectrum were reasonably well dispersed, although there were 
disparities in peak height, suggesting that the whole protein did not tumble together as a globular 
mass: rather some domains were more flexible than others (Fig 2.9A).  In addition, there seemed 
to be many overlapping peaks at ~8.4 ppm in the 1H dimension, indicating that the residues 
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associated were in a random coil, and the amide hydrogens were all not participating in secondary-
structures.  This is in accord with the prediction that the region between zinc-finger 5 and the zinc-
knuckle is disordered.  There were 166 peaks found, with 18 of those thought to belong to the 
asparagine/glutamine α-NH2 groups.  Comparing the number of backbone NH pairs found (141) 
with the number of residues (175) suggests that not all peaks were resolved, with many probably 
part of the overlapping blob at ~8.4 ppm.  These observations didn’t make the prospect of structure 
determination impossible, but they did point to the real possibility that the protein would be 
composed of individual zinc-fingers not interacting with each other.  This would not be informative 
structurally, beyond possibly identifying with residues interact with the PAS RNA.  To see if this 
goal would be achievable, a 17-nt PAS-containing RNA was mixed with 15N-labeled protein at a 
1.5x ratio of RNA—CPSF30 for running an NH-HSQC. 
The spectrum of CPSF30-ZF2-ZK with the 17mer PAS-RNA was very similar to the free 
protein, but there were some very noticeable differences (Fig 2.9A).  There were some peaks which 
showed shifts in their positions (chemical shift perturbations, or CSPs), but what stood out the 
most is the number of backbone-associated peaks that were missing (14 out of 148).  This showed 
that there were interactions, although the broadening of many peaks beyond detection suggests 
that they might be either weak or non-specific. 
In addition, there appears to be significant degradation of the RNA during the course of the 
2D-HSQC experiment.  Comparing 1D 1H spectra run before and after the 2D experiment shows 
that very narrow peaks appear, presumably from free nucleotides.  As a result, the disappearing 
peaks in the 2D-HSQC may due to some portion of the scans coming from RNA-bound protein, 
and the rest from free protein.  This would cause the peaks to smear, much in the same way as a 
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transient interaction. Since the individual scans are summed together on-the-fly during acquisition, 
it wasn’t possible to confirm this, or see the time-scale of RNA degradation. 
To see whether a random RNA could reproduce the CSPs seen when the WT PAS was 
added, RPL32 was used instead.  To solve the problem of degradation, many short 2D experiments 
were performed, interspersed with 1D experiments to probe RNA degradation.  After the whole 
experiment is done, only those 2D experiments with intact RNA would be added together to give 
good signal/noise.  To keep the time needed for each 2D experiment to a minimum, a different 
type of pulse-sequence was used: the NH-SOFAST-HMQC (Schanda et al. 2005).  This is much 
like the normal NH-HSQC, but instead of using a strong pulse to excite the 1H nuclei at all 
resonances, it uses a lower-power “shaped” adiabatic pulse to only excite the portion of the 
spectrum that contains the protein’s hydrogens.  The part of the spectrum with the water hydrogens 
get minimal excitation, and since they take the longest to relax back to ground-state, the scans can 
be repeated much more quickly.  The difference between HSQC and HMQC is simply the 
“pathway” the magnetic coherences take when going from hydrogen to nitrogen and back, which 
should have only small effects on the peaks observed (Cavanagh et al. 2007b). 
Summing three hour-long NH-SOFAST-HMQC experiments reproduced the same 
approximate peak-heights and signal-to-noise as the normal 8h-HSQC experiments, with about the 
same number of scans (128 vs. 192) (Fig 2.9B).  This time there were even more missing peaks 
when compared to the apo sample (36 out of 148).  The spectrum looked similar to the one with 
the PAS RNA added, but with notable differences in the missing peaks and position of those 
shifted.  The differences may be from the divergent sequences bound, or perhaps the limited time 
didn’t allow for as much RNA degradation, and therefore less of the apo signal was seen.  This 
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latter possibility would account for the increase in missing peaks in the RPL32 sample, if RNA 







Figure 2.9 NMR peak shifts when adding RNAs to CPSF30 are non-specific.  The 2D-NH 
spectrum of CPSF30-ZF2-ZK alone is shown in pink, and the spectrum with RNA is 
overlaid.  The regions in grey approximately encompass the chemical shifts of a random-
coil peptide.  A)  The 17mer PAS RNA mixed with CPSF30 (blue).  B)  the RPL32 RNA 
mixed with CPSF30.  Many of the same peaks are missing in both of the mixed samples, 
and most of those that shift also do so in both. 
 
All in all, the NMR results are a convincing argument that although CPSF30 does interact 
in some way with RNA, the interaction cannot be readily distinguished by NMR.  The similarities 
between the PAS and RPL32 RNA-containing samples were striking, suggesting that there was no 
molecular difference in the way CPSF30 interacted with each.  Together these results demonstrated 
that CPSF30 alone wasn’t enough carry out the primary function of mPSF: binding exclusively to 
the wild-type PAS.  This mirrored the results with WDR33, but with slightly weaker binding.  
Interestingly though, the EMSA results showed that binding was only present when zinc-fingers 
besides the ones previously identified where included (Fig 2.8).  These were deleted in a previous 
study, and there was no effect in binding the PAS in the context of mPSF (Chan et al. 2014).  This 
hints that these other zinc-fingers (and knuckle) could provide non-specific RNA interactions, to 
either increase the PAS-binding efficiency or to guide the RNA to other parts of the 3’-end 
processing complex. 
Neither of the regions of the proteins implicated in PAS binding are competent on their 
own to discriminate between a random RNA sequence and AAUAAA (Fig 2.8, 2.3).  An obvious 
explanation is that they have to bind the PAS together, and that synergistically they can form a 
specific interface for the RNA.  To test whether this is true, the two were mixed together and 
incubated with the FAM-labeled RNA.  The result was negative: identical binding at the 
concentration tested as WDR33 alone, with no “super-shifted” band to indicate a complex of 
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WDR33—CPSF30—RNA (Fig 2.10).  This still did not preclude the need to form a larger complex 




Figure 2.10 EMSA of CPSF30 mixed with WDR33 show no additional binding. EMSA of 
the mixed sample compared to WDR33 alone.  It is clear that there is no difference in the 
two sets, such as “super-shifts” due to both proteins binding.  The lowest concentration of 
WDR33 tested bound ~1/2 of the RNA, and higher concentrations appeared to oligomerize 
since they didn’t enter the gel and stayed in the wells. 
 
2.3.8 Expression and Purification of mPSF 
Since WDR33 and CPSF30 by themselves did not result in viable PAS binding, it was 
decided to express them together with CPSF160 and FIP1 to form mPSF.  A baculovirus with all 
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the proteins cloned under viral promoters was constructed.  WDR33 and CPSF30 were cloned into 
the pFL vector, and CPSF160 with-or-without FIP1 was cloned into the pUCDM vector.  The latter 
vector was recombined into pFL using the Cre-Lox system, and inserted into the baculovirus 
genome with Tn7 recombination (Fitzgerald et al. 2007).  Test expressions showed that the 
complex was formed and pulled down from lysate using Ni-NTA beads with an N-terminal Histag 
cloned onto WDR33, but only when FIP1 wasn’t present.  When it was co-expressed, there was 
little to no yield of the complex.  It was then decided to express mPSF without FIP1, using the 
longest viable construct of WDR33 (aa. 1-572), and full-length CPSF160 and CPSF30.   
This combination was scaled up to 1 liter, and purified by Ni-NTA with a high-salt wash 
to remove nucleotides, followed by a heparin column and gel filtration using a Sephadex-6 10/30 
column (SP-6).  The elution from the gel-filtration showed a very broad peak, possibly consisting 
of two overlapping peaks (Fig 2.11A).  The earlier peak would correspond to the complex being a 
trimer, and the later one as a monomer.  All three proteins were in both overlapping peaks, but the 
monomer peak had many other contaminant proteins.  Unsurprisingly, CPSF30 showed the same 
pattern of degradation observed when it was expressed in E. coli, with the later peak having mostly 





Figure 2.11 Purification of the mPSF complex using gel-filtration.  A)  Purification of the 
entire sample, after ion-exchange.  B)  Second gel-filtration using peaks 18-34.  The peak 
remained quite broad, with a high (>1) ratio of 260/280 absorbance (260: red, 280: blue), 
indicating the presence of nucleic acid contamination.  The calculated molecular weight, 
using the elution volume of the center of the peak corresponded to a trimer.  C)  Second gel-
filtration using peaks 35-46.  The molecular weight was calculated to be approximately a 
monomer using the molecular weight of mPSF. 
 
The presumably separable peaks were each pooled, concentrated, and re-run on the SP-6 
column.  The re-run peaks behaved as previously:  the first was a trimer with a broad peak (Fig 
2.11B), and the second a monomer (Fig 2.11C).  The trimer peak had a high 260/280 absorbance 
ratio, indicating that there remained a large amount of bound nucleic acids despite the salt-wash 
and the purification with a heparin column.  It was thought that perhaps the complex was binding 
RNA, and that this RNA bridged multiple copies of mPSF, making it appear as a trimer.  To test 
 
 44 
whether removing RNA would make both peaks behave the same, RNase A was titrated into 
aliquots of the trimer peak, and the results were run on a Blue-Native PAGE gel along with the 
monomer peak (Wittig et al. 2006).  The results showed that without RNase A, the trimer sample 
did not appear to even enter the gel, indicating that is existed as a very high molecular weight 
species (Fig 2.12).  But with increasing amounts of RNase A, there appeared a band not in the 
RNase A alone lanes.  This band still ran larger than the one in the monomer lane, suggesting that 
although the nucleic acids were digested, this complex was still a larger species.  So therefore, the 
trimer peak really was a larger species than 1:1:1 of WDR33—CPSF30—CPSF160, but the native-








Figure 2.12 Native-blue PAGE of mPSF with RNase indicated that mPSF is bound to 
nucleic acids during purification.  Addition of RNase allowed the trimer sample to enter 
the gel, leading the appearance of a distinct band.  The band observed in the monomer sample 
still ran faster on the gel than this new trimer band, indicating that the timer sample was still 
larger. 
 
2.3.9 EMSA of mPSF 
The trimer peak with no RNase was used to perform an EMSA using the WT and mutant 
SV40 PAS RNAs, just as with WDR33 and CPSF30 alone (Hellman and Fried 2007).  The 
concentration of mPSF was not accurate given the amount of nucleic acid contamination, and was 
an estimate based on SDS-PAGE.  Yet despite this short-coming, the EMSA clearly demonstrated 
that the complex could do what the individual proteins could not:  the WT RNA was bound, while 
the mutant RNA was not (Fig 2.13).  Somehow, the addition of CPSF160 conferred selectivity 
onto the proteins.  From this, it was decided that to pursue the structure of each individually would 
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not be useful, and that instead the full WDR33—CPSF30—CPSF160 complex would be used for 
further structural studies of PAS-RNA binding. 
 
Figure 2.13 EMSA of the mPSF complex mixed with FAM-labeled RNA shows specific 
binding.  The trimer mPSF complex could bind to wild-type PAS RNA, but not mutant 
RNA.  The concentration of complex was unknown due to the large nucleic acid 
contamination rendering absorption at 280 nm unreliable. 
 
2.3.10 Electron Microscopy of mPSF 
To further characterize the complex and to determine the possibility of obtaining a 
structure, the two peaks were used to perform negative-stain electron-microscopy (NS-EM).  To 
digest the RNA bound to the trimer sample but also not complicate the results with excess RNase, 
RNase I with an MBP tag was incubated with the sample, then removed with amylose resin (Fig 
2.14A).  Various dilutions of the complex were applied to a copper EM grid coated with amorphous 
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carbon, and stained with uranyl acetate.  The grids were imaged on a JOEL JEM-1230 microscope 
with a Gatan 4k x 4k CCD detector, for a maximum magnification of 60,000x at the Simons 
Electron Microscopy Center, part of the New York Structural Biology Center. 
 The monomer samples had heterogenous clumps of what appeared to be aggregated 
protein.  The RNase-treated trimer sample also had clumps of protein, but there appeared to be 
some smaller and homogeneously-sized particles.  Very little of the grid had acceptable staining, 
so only a few micrographs were collected and only 2636 particles were picked.  Despite the low 
number, the particles were subjected to 2D classification with Relion into 25 classes (Scheres 
2013).  As expected from using such a small number of particles, there were few classes with any 
population, and the average from those that did have some particles was very low resolution.  Only 
one class (class 5, 6.2%, 165 particles) had a discernable shape (Fig 2.14B).  To see if this class 
gave any hint of a real projection of the complex, homology models of CPSF160 (template DDB1, 
PDBID 4E54) and the WD40 domain of WDR33 were modeled using SWISSMODEL 
(Waterhouse et al. 2018) and overlaid onto the 2D projection in Chimera (Pettersen et al. 2004).  
The four WD40 domains fit onto the observed density projection, with WDR33 capping the bottom 




Figure 2.14 Preliminary negative-stain EM of the mPSF complex shows some classes in 
agreement with homology models.   A)  SDS-PAGE of the samples used for EM.  B)  The 
top 3 2-D class averages from the micrographs of the trimer mPSF sample.  All other classes 
were noise. B) The 2nd class average (27% of the particles) overlaid with homology models 
of CPSF160 and WDR33 in Chimera. 
 
Despite this, further study of complex by EM was frustrated by a lack of reproducible 
expression.  Repeated attempts to re-express the complex showed small amounts of WDR33 and 
CPSF30 expression, with no CPSF160 visible by SDS-PAGE.  Eventually, the solution was found 
by another member of the lab:  use two different viruses, one with WDR33 only and the other with 
just CPSF160.  CPSF30 was expressed as an MBP/TEV-fusion in E. coli, and mixed with the 
WDR33—CPSF160 sample after purification.  In order to express the CPS160—WDR33 sub-
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complex, a larger aliquot of the CPSF160-containing virus was added to the Hi5 cells compared 
to the WDR33-containing virus (2-3x), which appeared to alleviate the expression issue.  Samples 
prepared in this manner were then used to determine the structure of WDR33—CPSF30—
CPSF160 in complex with the PAS RNA using cryo-EM by Yadong Sun in collaboration 
with Yixiao Zhang from the Tom Walz lab at Rockefeller Universtity (Sun et al. 2017). 
 
2.3.11 Structure of mPSF binding to RNA 
As mentioned previously (see ch. 1) mPSF contains three proteins visible by cryo-EM: 
CPSF160, the N-terminus of WDR33, and the first three zinc-fingers of CPSF30.  CSPSF160 
contains three WD40 domains in a trefoil arrangement, with the WD40 domain of WDR33 binding 
to the bottom of two of the three (Sun et al. 2017; Clerici et al. 2018).  CPSF30 wraps around both 
of these proteins, and creates a pocket to bind the RNA along with WDR33.  The pocket is like a 
hand grasping the RNA, with the “palm” being the WD40 domain of WDR33, the “fingers” zinc-
fingers 2 and 3 from CPSF30, and the “thumb” the N-terminal part of WDR33 (Fig 2.15A).  These 
“fingers” and “thumb” bind to the bases of the RNA in a sequence-specific manner, giving rise to 
the specificity that was missing when each bound to the RNA alone. 
Within the RNA, four of the bases interact specifically with zinc-fingers 2 and 3 of CPSF30 
(Fig 2.15B).  Surprisingly and satisfyingly, bases A1 and A2 interact with zinc-finger 2 in almost 
the same manner as A4 and A5 interact with zinc-finger 3.  The N1 atoms of A1 and A4 hydrogen 
bond with the backbone of the zinc-fingers, and each is base-stacked against a phenylalanine (F84 
and F112).  The N1 atoms of A2 and A5 also both hydrogen bond with the CPSF30 backbone and 
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base stack, this time against H70 and F98.  Additionally, the N6 amine groups from both A1 and 
A4 interact with carbonyl oxygens in the CPSF30 backbone.   
The differences between the two pairs of nucleotides include the base of A2 lying close to 
and possibly interacting with K78 and K77, N7 of A4 interacting with K69, and N3 of A5 with the 
backbone of WDR33.  Most interestingly, the bases of U3 and A6 behave quite differently from 
these two pairs.  They are both swung to the opposite side of the sugar-phosphate backbone in 







Figure 2.15 PAS RNA binding by the mPSF complex shows specific contacts to CPSF30 
and WDR33.  A)  mPSF (PDBID 6DNH) is shown with surface representations of CPSF160 
(magenta), CPSF30 (green) and WDR33 (WD40 domain in yellow, N-terminus in orange), 
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and stick representation of the PAS RNA.  The “fingers” of CPSF30 zinc-fingers 2 and 3, 
“palm” of WDR33 WD40 domain, and the “thumb” of the WDR33 N-terminus can be seen 
to create a channel through which the PAS RNA passes.  B)  The same view as the left panel 
in (A), but with the proteins represented as cartoons.  Critical residues in CPSF30 and 
WDR33 are shown as sticks.  Hydrogen bonds between the RNA bases and protein are 
indicated with orange dashed lines, and those in the Hoogsteen base-pair are red.  The zincs 
are shows as grey spheres. 
 
2.3.12 Characterizing PAS RNA binding to mPSF using Fluorescence Polarization  
To further characterize and validate the binding of PAS-RNA observed in the structure, 
fluorescence polarization (FP) experiments were carried using various fluorescein-labeled RNAs.  
FP is a method that utilizes the delay time between the excitation of a fluorophore and its 
subsequent emission to indirectly measure the rotational correlation time of a fluorophore-tagged 
target (Rossi and Taylor 2011).  If polarized light is used to excite a sample of randomly-oriented 
fluorophores, only those arranged in particular orientations with respect to the polarization will 
become excited.  Once they relax back to their ground state, the emitted photons will also be 
polarized with respect to these fluorophores.  If the fluorophores rotate very fast compared to the 
lifetime of the excited state, then the bulk polarization of the emitted light will be random 
(isotropic).  Conversely, if they rotate very slowly, then the light will be somewhat polarized 
(anisotropic).   
For example, by attaching the fluorophore to PAS-containing RNA, the binding of mPSF 
can be detected as an increase in the observed polarization anisotropy.  By varying the 
concentration of mPSF while holding the fluorophore-labeled RNA constant, the resulting change 
in polarization anisotropy can be modeled with a simple quadratic binding equation, with the Kd 
determined by non-linear least-squares fitting.  Once a Kd of a fluorophore-labeled RNA is found, 
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using unlabeled RNAs to competitively out-bind the labeled RNA can then be modeled and used 
to find the Kd of these new RNAs by titrating them into a fixed amount of mPSF and labeled RNA. 
In carrying out these experiments, the mPSF complex was made in the same manner as that 
which was used for EM, with some modifications.  A shorter construct of WDR33 was used (1-
425), leaving out a C-terminal region not observed in the structure.  In addition, CPSF30 was either 
cloned into the WDR33-containing virus and expressed with the other two proteins in Hi5 cells, 
or cloned with a His-tagged SUMO tag and co-expressed with a FIP1 fragment (159-200) in E. 
coli.  This latter modification of protocol was found to dramatically improve the yield and behavior 
of CPSF30, compared to expressing the MBP-fusion by itself. 
In order to quantify RNA binding to mPSF a series of FP experiments were first carried 
out.  These experiments used the same 17mer RNA sequence that was used for structure 
determination. For the fluorophore tag, 6-Carboxyfluorescein (FAM) was covalently linked to the 




Table 2.1.  Kd’s of RNA binding, determined with Fluorescence Polarization 
Protein RNA Kd (nM)1 
CPSF-160 (full-length)–WDR33 (1-
425)–CPSF-30 (full-length),  
Fip1 (159-200) 
FAM-AACCUCCAAUAAACAAC 0.28±0.07 
      FAM-CAAUAAACAAC 0.32±0.04 
           AAUAAA-FAM 8.05±0.45 
          CAAUAAACAAC 3.10±0.17 
          CAAUAAAC 57±18 
           AAUAAAC 110±68 
           AAUAAA >2,000 
          CGAUAAACAAC >500 
          CAUUAAACAAC 17.2±2.3 
          CAAUGAACAAC n. b.2 
          CAAUACACAAC >2,000 
FAM-AACCUCCAAGAAACAAC 15.5±1.3 
FAM-AACCUCCAACAAACAAC 50.3±9.2 
          CAACAAGCAAC n. b.2 




CPSF-30 wild-type3 “ 0.19±0.03 
CPSF-30 H70A mutant3 “ 16.8±1.2 
CPSF-30 R73A mutant3 “ 3.20±0.26 
CPSF-30 K77A/K78A mutant3 “ 0.34±0.05 
CPSF-30 F84A mutant3 “ 1.46±0.17 
CPSF-30 F112A mutant3 “ 27.2±2.6 
0.5x CPSF-304 “ 1.76±0.18 
1x CPSF-304 “ 0.56±0.05 
5x CPSF-304 “ 0.19±0.03 
10x CPSF-304 “ 0.10±0.02 
20x CPSF-304 “ 0.30±0.03 
1. The dissociation constants for FAM-labeled RNAs were measured by direct fluorescence 
binding assays, while those for unlabeled RNAs were measured by competition fluorescence 
binding assays. Each experiment was repeated 3 times, and the reported values are mean±standard 
error.  
2. n.b., no binding observed 
3. The mixture also contained CPSF-160 (full-length)–WDR33 (1-425), and Fip1 (159-200) was 
co-expressed with CPSF-30. CPSF-30 was at 5-fold molar excess.  
4. The mixture also contained CPSF-160 (full-length)–WDR33 (1-425), and Fip1 (159-200) was 





 Using the WDR33—CPSF30—CPSF160 complex with 1 µM FIP1 (159-200) added to the 
buffer to limit aggregation, a Kd of 0.28 ± 0.07 nM was found for the 17mer RNA (Table 2.1, Fig 
2.16), in line with previously published results using a different fluorophore-tag (Clerici et al. 
2017).  The same experiment without the added FIP1 resulted in a Kd of 0.25 ± 0.05 nM, not 
significantly different and indicating that FIP1 did not participate in the interaction with RNA 
(p=0.24).  This was supported by a titration of FIP1 alone, which shows no binding even at 10 µM. 
Although only density for the 6 residues of the PAS hexamer were visible in the cryo-EM 
map used for model building, there were 17 residues present in the RNA used (7 upstream and 4 
downstream).  Two additional FAM-labeled RNAs were used to test whether these other residues 
had any effect on the binding strength of the mPSF for RNA (Fig 2.16).  First, a 5’-labeled 11-mer 
that contained the same downstream sequence, but only had one base upstream of the PAS was 
tested, yielding a Kd of 0.32 ± 0.04 nM, which isn’t significantly different than that of the 17-mer 
(p=0.34).  The second RNA tested was a 6-mer 3’-labeled with FAM through a phosphate group.  
Using this the Kd was found to be 8.05 ± 0.45 nM , significantly higher than the 17 and 11-mers 
(p < 0.001).  There are two possibilities for this change:  either bases outside of the PAS were 









Figure 2.16 Various lengths of RNA and mutations in the PAS affect mPSF binding. 
Fluorescence polarization binding assays of the CPSF160—WDR33—CPSF30 ternary 
complex with labeled 17-mer, 11-mer, and 6-mer AAUAAA PAS RNAs, as well as labeled 
17-mer RNAs with AAGAAA and AACAAA as the PAS (nucleotides distinct from 
AAUAAA are indicated by underline). The curves represent fitting to the binding data. 
 
 In order to test the first possibility, the unlabeled 6-mer was used to compete against labeled 
17-mer (Fig 2.17).  Surprisingly, the Kd for this RNA was drastically different:  there was only a 
small amount of binding even at 2000 nM.  This indicated that residues outside of the PAS are 
critical for binding, conflicting with the modest change in Kd seen when the labeled 6-mer was 
used.  It was thought that perhaps the phosphate used to connect the FAM label to the 3’ of the 6-
mer might mimic the connection to an additional base, so longer unlabeled RNAs were tested to 





Figure 2.17 RNA length affects PAS binding by mPSF.  Competition fluorescence 
polarization binding assays of the CPSF160–WDR33–CPSF30 ternary complex with 
unlabeled 11-mer, 8-mer, 7-mer, and 6-mer AAUAAA PAS RNAs. Labeled 17-mer 
AAUAAA PAS RNA was used as the reporter. hFip1 (159–200) is included in all the assays. 
Error bars are ±1 standard deviations from triplicate experiments. 
 
First, one additional residue was added to the 3’-end of the 6-mer to mimic the FAM label 
connection.  The Kd decreased to 110 ± 68 nM, much better than the 6-mer, but still ~300x that of 
the longest labeled RNAs.  It was concluded that the labeled 6-mer does indeed use the additional 
3’-phosphate to bind, but there are also some other interactions between mPSF and the FAM 
moiety that must increase the affinity.  Next, an additional residue was added to this 7-mer 5’ of 
the PAS, which decreased the Kd even more to 57 ± 18 nM.  The modest change indicated that 
although the 5’ nucleotide may help PAS binding, it still wasn’t enough to reproduce the tight 
binding observed with the labeled 11-mer.  Therefore, an unlabeled version of the 11-mer was 
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tested, and this had a Kd of 3.10 ± 0.17 nM, much closer to that of the longest labeled RNAs.  The 
fact that it is still ~10x that of the labeled 11-mer suggests that the 5’-FAM label helps binding to 
the mPSF, much like the 3’-FAM but with somewhat less of an effect. 
The earlier EMSA results had shown that WDR33 and CPSF30 alone could bind RNA 
weakly and without specificity.  In order to quantify these interactions and to compare them to that 
of the whole mPSF complex, each was tested with FP separately or in combination (Fig 2.18A).  
WDR33 alone didn’t start to show binding until its concentration was greater than 10 nM, in line 
with the earlier EMSA results.  The complex of CPSF30—FIP1 (full-length CPSF30 by itself was 
not stable) also showed a very high Kd (>5 µM), in the same range as the observed EMSA results.   
Since CPSF160 appears to serves as a scaffold on which CPSF30 and WDR33 are arranged 
to bind RNA in the complex structure, it was thought that perhaps a binary complex with CPSF160 
might help each separately to bind.  But the results did not bear this out:  all curves resembled 
WDR33 alone (no binding when < 10 nM).  The CPSF30—FIP1 with added CPSF160 did appear 
to bind at a lower concentration than without CPSF160, but it isn’t known if this if from a complex 
between them or just CPSF160, which wasn’t tested alone.  The latter possibility would be in line 
with previous reports of CPSF160 binding to RNA.   
To test whether CPSF160 was indeed needed to be a scaffold, WDR33 and CPSF30—FIP1 
were mixed to see if they could bind the RNA tightly without CPSF160.  They had binding curves 
that resembled WDR33 alone, indicating that CPSF160 was really needed to hold the two proteins 
in an orientation competent for tight RNA binding.  Finally, the recapitulation of the low Kd found 
with the CPSF160—CPSF30—WDR33 complex using these separate components was attempted 
(Fig 2.18B).  Various ratios of CPSF30—FIP1 to CPSF160—WDR33 were tested, with maximal 
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binding found with 5x CPSF30—FIP1 (Kd=0.19 ± 0.03 nM).  Yet even with 1x added, the binding 
was not significantly different from this value (Kd=0.56 ± 0.05 nM, p=0.17), indicative of a high 
affinity between the two sub-complexes. 
To test the binding mode of CPSF30 observed in the structure, a series of mutations to 
alanine were cloned and used for FP studies (Fig 2.18C).  The CPSF30 mutants were co-expressed 
with FIP1, and mixed with the WDR33—CPSF160 sub-complex at a 5x excess.  Of those tested, 
mutating F112 and H70 had the largest effects on the Kd (140 and 90-fold increase, respectively).  
These both π-stack against an adenine base (A4 and A2), much like F84, which stacks against A1.  
Yet mutating this residue only results in a 8-fold increase in Kd, suggesting that this interaction is 
not as crucial as the other two, which are deeper into the RNA binding pocket. 
 Mutations to alanine of positively-charged residues that are thought to interact with the 
phosphate backbone were also tested.  A double-mutation of K77 and K78 had only an 
insignificant two-fold increase in Kd (p=0.19).  These residues are in proximity to the A2 and U3 
phosphates, but the RNA backbone is mostly exposed to the solvent.  In contrast to these residues, 
mutating R73 increased the Kd 17-fold (p<0.001).  This residue interacts with the A4 phosphate, 
and has good electron density.  This phosphate has less access to the solvent compared to the 
previous two, suggesting why R73 is needed to stabilize the binding. 
Taken together, these results generally validate the binding mode observed in the published 
mPSF structure, and another published shortly after of the mPSF with a slightly different PAS-
containing RNA (Clerici et al. 2018).  The CPSF30 mutations and the lack of tight binding from 
an incomplete complex all correlate well with the two structures, both of which show the exact 
same PAS binding mode.  The result that is unexplained by either structure is the increase in 
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binding when the RNA is expended beyond one nucleotide after the PAS.  The Sun et al. structure 
has no density beyond the +1 position, giving no hint as to what might stabilize an additional 
phosphate (Fig 2.23A).  The Clerici et al. mPSF structure does have an extended density, but the 
fitted model does not have any charged residues interacting with the phosphate (Fig 2.23B). 
Comparing the structures of the human mPSF to the equivalent yeast complex shows that 
the overall architecture is very similar (Casañal et al. 2017).  Cft1 (equivalent to CPSF160) also 
forms a three-WD40 trefoil that binds the WD40 domain of Pfs2 (WDR33) and the N-terminal 
region and first zinc-finger of Yth1 (CPSF30).  The structure of Yth1 also includes its second zinc-
finger, but the rest (zinc-fingers 3-5) are not visible and are presumably disordered (the complex 







Figure 2.18 PAS binding requires three components of mPSF. A) Polarization binding 
assays between the labeled 17-mer AAUAAA PAS RNA and titrations of mixtures 
containing WDR33, CPSF30, CPSF160, and hFip1 cannot achieve high-affinity RNA 
binding alone. Only the quaternary complex with all four displays ~1 nM binding.  Error 
bars are standard deviations from three repeats.  B) Both CPSF30 and WDR33 are required 
for PAS RNA binding. Fluorescence polarization binding assays be- tween the labeled 17-
mer AAUAAA PAS RNA and mixtures of the CPSF160–WDR33 binary complex and 
CPSF30 (full-length, co-expressed with hFip1) at increasing molar ratios.  C)  Fluorescence 
polarization binding assays between the labeled 17-mer AAUAAA PAS RNA and mixtures 
of the CPSF160–WDR33 binary complex and CPSF30 wild-type and mutants (co-expressed 





Comparing the sequences of zinc-fingers 2-3 of CSPF30 and Yth1 shows that the residues 
identified as critical to PAS binding are conserved, and overlaying the ZF2s shows that those 
observed are in equivalent positions (Fig 2.19A,B).  Additionally, Pfs2 has F127 in the same 
position as WDR33-F153, part of the “clamp” that stacks against human A6.  Yet Pfs2 lacks the 
N-terminal extension present in humans that contains WDR33-F43, the other side of the “clamp”.  
The conservation of the residues that bind to the AA-dinucleotides but not the Hoogsteen base-
pair might explain the lower consensus of equivalent of the PAS in yeast, known as “positioning 
element” (PE).  The PE has significant degeneracy, with AAUAAA and AAAAAA as the most 




Figure 2.19 PAS binding residues are conserved in the yeast CPSF30 homolog (Yth1).  A)  
Alignments of CPSF30 (or Yth1), zoomed to show zinc-fingers 2-3.  Residues critical for 
PAS binding are highlighted with green dots.  The alignment is the same as that shown in 
Figure 2.5.  B)  Overlay of zinc-finger 2 from human CPSF30 (dark green) bound to the PAS 
(grey) with zinc-finger 2 from Yth1 (light green, PDBID 6EOJ), in approximately the same 






2.3.13 FP Using Alternative PAS Sequences 
Although the canonical AAUAAA hexamer is present in most mammalian pre-mRNAs, 
there are still about 40% that do not use it as the polyadenylation site (Tian et al. 2005; Wang et 
al. 2018).  There are other less frequent PAS sequences, like AUUAAA which accounts for ~15% 
of the pre-mRNAs.  Other single-nucleotide variations of the canonical PAS each account for ≤2% 
of the rest of the pre-mRNAs (Tian and Manley 2016).  Different PAS sequences may be used as 
alternative polyadenylation sites of the same pre-mRNA, and may constitute a way that the cell 
may switch the sites (Gruber and Zavolan 2019).  If a weak PAS also has other upstream and 
downstream elements that are recognized by other subunits of the machinery, it may be chosen 
when those subunits are present in high amounts, but not when they are absent.  Therefore, it was 
decided to test the strength of these PAS sequences in comparison to the canonical one.  To do 
this, unlabeled 11-mer RNAs with various PAS sequences were titrated against a fixed 
concentration of the FAM-labeled 17-mer and mPSF.  Various positions of the PAS were changed 
to match the observed non-canonical sequences:  GAUAAA (~1% frequency), AUUAAA (~15% 





Figure 2.20 Variations in the PAS sequence affect mPSF binding.  A) Competition 
fluorescence polarization binding assays of the CPSF160–WDR33–CPSF30 ternary 
complex with unlabeled 11-mer RNAs containing variations of the A1, A2, A4, and A5 
bases.  B) Competition fluorescence polarization binding assays of the CPSF160– WDR33–
CPSF30 ternary complex with unlabeled 11-mer RNAs containing variations of the U3–A6 
Hoogsteen base pair, AAAAAU, and AACAAG.  hFip1 (159–200) is included in all the 
assays. Error bars are ±1 standard deviations from triplicate experiments.   
 
Unsurprisingly, the results mirrored the frequency of the non-canonical PAS sites observed 
in mammalian pre-mRNAs (Fig 2.20A).  The second most frequently observed PAS (AUUAAA) 
bound with a Kd of 17.2 ± 2.3 nM, just ~6-fold higher than the canonical PAS.  The rest of the 
PAS sequences bound much less tightly, with only GAUAAA showing any binding at 
concentrations >2000 nM.  The other two had only minor binding at 5000 nM, the highest 
concentration tested.  Another PAS sequence that is observed AAGAAA (~3% frequency), which 
was used for the previous EMSA experiments as part of a FAM-labeled 17mer-RNA as a control.  
When mPSF was titrated directly against this RNA, a Kd of 15.5 ± 1.3 nM was found.  This is 
~55x that of the 17-mer with the canonical PAS, putting it in-between AUUAAA and the rest of 
the PAS sequences, in line with the frequency with which it is used as a polyadenylation site.   
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These results indicate that some PAS sequences cannot bind strongly to mPSF, but are still 
used for polyadenylation-site selection.  Therefore, in these cases, there must be other elements in 
the pre-mRNA that bind to other complexes in the 3-end processing machinery.  Varying the 
activity and/or concentration of these other complexes could provide a way to switch the use of 
the weaker sites on or off, giving a way that alternative polyadenylation may be carried out for 
some pre-mRNAs.   
The Hoogsteen base-pair (U3 and A6) do not make any base-specific contacts within the 
mPSF—PAS complex, but are highly conserved within the utilized PAS sites.  The only contact 
between the two bases and mPSF are two phenylalanines that stack on either side of U6: F43 and 
F153 in WDR33.  This base-pair is presumably needed to hold the two AA-dinucleotide pairs of 
A1-A2 and A4-A5 in the correct orientations, but it isn’t clear whether other Hoogsteen pairs could 
perform the same function.  To test this, the PAS in the unlabeled 11-mer RNA was mutated to 
AAAAAU or AACAAG (the underlined bases would be part of the Hoogsteen base-pairs).  When 
tested, neither showed any binding even at concentrations up to 5000 nM (Fig 2.20B).  
The lack of binding for the A-U pair is easily explained.  In a Hoogsteen base-pair within 
a double-helix, the purine is in a syn conformation with respect to the ribose, and the pyrimidine 
is in an anti one (Fig 2.21A).  In the mPSF—RNA structure, the bases are arranged so that each 
can be in the anti conformation.  When these two are switched, they now both have to adopt the 
syn conformation (Fig 2.21B).  This brings the O2 of U6 into conflict with its phosphate group, so 
the γ-bond of the ribose has to rotate to prevent them from clashing, shifting the base ~1 Å (Fig 
2.21C).  To compensate, the A3 also needs to shift ~1 Å to bring its N6 amino group within 
hydrogen-bonding distance of the U4 O4 atom.  These both lead to a large deformation of the 
whole ribose-phosphate backbone that disrupts the binding of the rest of the PAS. 
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Conversely, the C-G Hoogsteen base-pair should be in almost exactly the same orientation 
as the U-A one, and the extra N2 amino group on the guanosine doesn’t appear to clash with any 
part of the surrounding proteins (Fig 2.21D).  Yet it doesn’t bind, perhaps reflecting an underlying 
lack of stability of the C-G Hoogsteen pair itself.  In comparison to the two hydrogen bonds in a 
Hoogsteen A-U pair, anti neutral cytosine would only form one hydrogen bond with syn guanosine 
between its N4 amino group and guanosine O6.  It is only when cytosine is protonated on its N3 
position that it could form another hydrogen bond with the N7 of guanosine.  Although the pKa of 
the cytosine N3 has been observed increase in the context of the C-G Hoogsteen base-pair from 
~4.2 to ~7.1, the population of G-C was still estimated to be ~20x less than that of A-T when 
studied in the context of DNA at 25mM NaCl at pH 7 (Nikolova et al. 2013).  This population 
difference was observed to increased with higher salt, so combined with the slightly basic nature 
of the buffer (pH=8.0), it is possible to see why the A-U Hoogsteen base-pair formed while the C-




Figure 2.21 Hoogsteen variants prevent PAS binding.  A)  Schematics of Hoogsteen base-pairing, 
highlighting the syn-anti nucleotides needed in the context of double-helices.  The flipped-out U3 
and A6 of the PAS are positioned to be both anti. The protonated N3 of cytosine is highlighted in 
blue.  Figures made using ChemDraw 18.  B)  Structural changes that accompany mutating the 
bases to switch the Hoogsteen pair (U3A and A6U).  The original sequence is in light gray, and 
the mutated version in green.  C)  overlay of A6 and U6, showing the rotation of the γ-bond to 
accommodate the flipped ring.  D)  No large structural changes accompany the mutants U3C and 





2.3.14 Reprocessing Cryo-EM of mPSF 
The observed necessity of RNA bases after the +1 position 3’ of the PAS for binding to 
mPSF was not supported by the cryo-EM structure, since there was little electron density after this 
residue (AAUAAAC).  It was thought that perhaps re-classifying the data used to model that 
structure might help to solve this discrepancy.  The final step in the classification used for 
publication used a mask that encompassed the whole area around CPSF30 to filter out those with 
only CPSF160—WDR33 (Sun et al. 2017).   
The idea was that focusing the classification on just the region around the RNA —starting 
with just the particles used for the CPSF30—CPSF160—WDR33—RNA complex— may remove 
any mPSF that had no RNA bound from the reconstruction.  The prior classification that selected 
the particles used to model mPSF used a mask around the whole region of CPSF30 to separate 
those that contained the protein and those that did not.  Out of 456 k particles, the classification 
found 174 k that had CPSF30 (38%).  It was hoped that by further classifying these 174k particles 
using just the RNA-containing region, two classes could be obtained: those with RNA and those 
without.  This would in theory remove any particles whose empty density would “spoil” the 
average, and result in stronger RNA density. 
The particles were assumed to be well-aligned, with no movement of the RNA-binding 
region compared to the rest of the complex when RNA was present or absent.  For this reason, no 
rotations or translations were allowed during this round of classification:  the only variable 
sampled was the occupancy in each of 8 classes.   
 To accomplish this, the region around the RNA in the prior map was selected using 
Chimera, expanded 10 Å and smoothed to create a binary mask (Fig 2.22A).  Using Relion, this 
 
 70 
mask was used in an iterative classification of the 173,632 aligned particles based only on the 
density within the masked region.  The classification was allowed to go for 30 iterations, and 
monitored through the populations of each class, and how many particles “jumped” between any 
two of them.  At iteration 16, it appeared that the class populations became somewhat stable, so 
the densities of each at this iteration were examined (Fig 2.22B).  Only class 6 (87% of the 
particles) had good density for the RNA, with the rest either having none or broken density.  The 
particles in class 6 were then re-refined, yielding a map with negligibly lower overall resolution 
(3.5 vs. 3.4 Å). 
 
 
Figure 2.22 Classification of mPSF particles using an RNA mask.  A)  The mask used for 
classification is shown as orange mesh over the mPSF model.  B)  The results of the 
classification.  Only the density within the mask is displayed.  Only Class 6 has good RNA 
density.  The rest of the classes all have density for CPSF30 zinc-finger 2 (upper left), zinc-
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finger 3 (upper right), and a large density encompassing part of the PAS RNA and WDR33 
(lower right). 
 
 Examining the EM density 3’ of the PAS in the new map showed some beyond the C(+1), 
allowing the phosphate of the A(+2) to be placed (Fig 2.23C).  The extra density was somewhat 
visible in the original map, although it was broken and couldn’t easily be distinguished from noise 
(Fig 2.23A).  The oxygens of the A(+2) phosphate were now seen to be ~3 Å from K50 and ~6 Å 
from R47 in WDR33, providing a possible reason for the ~18-fold decrease in Kd observed when 
the 3’ of the PAS RNA was extended beyond the +1 position. 
Luckily, these two residues were mutated in a prior study, and the change in Kd measured 
with fluorescence polarization (Clerici et al. 2017).  This study was prior to their determination of 
mPSF bound to PAS-RNA (Clerici et al. 2018), so instead of the mutations being targeted, they 
mutated pairs of positively charge residues to alanine in the general area they thought WDR33 
would bind RNA.   The first pair mutated was R49-K50, which resulted in an increase of Kd of ~ 
5x.  Given that there are two residues mutated, it is difficult to tell if the Kd change is truly from 
the K49 interaction with the +2 phosphate rather than K50.  K50 is within 3 Å of the +1 phosphate, 
but so is R54, so it isn’t clear whether both are needed to stabilize it.   
The second pair mutated was K46-R47, which resulted in a ~12x increase in the Kd.  This 
result is a little bit clearer, since in all mPSF structures K46 is not near any RNA.  In addition, the 
change in Kd is very similar to the increase observed when the PAS-RNA is shortened from an 11-
mer to an 8-mer (11x).  This lends a satisfying credence to this hypothesis that R47 is responsible 
for the change, but for the position of the +2 phosphate in their structure.   
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 The placement of the A(+2) phosphate in the new model using the RNA-mask classified 
particles is inconsistent with the Clerici et al. published structure of mPSF with RNA bound.  Their 
structure has density into which they modeled the +2 phosphate closer to WDR33, so that it clashes 
with R47 in our new model (Fig 2.23B).  In their model, the R47 sidechain bends away from the 
RNA, and there is nothing left to stabilize the +2 phosphate.  It may be possible that the divergent 
conformations are due to the differences in RNA sequence: they have guanosine in the +1 position, 
whereas all the RNAs used in this thesis have cytosine.  Oddly, they don’t connect this model to 





Figure 2.23 Extra RNA density is visible in class 6 of the RNA-masked Classification.  A)   
The EM density map whose particles are used for RNA-masked classification (EMD7112), 
with the fitted model (PDBID 6DNH).  B)  Density from Clerici et al.  (EMD20860), with 
their fitted model (PDBID 6FBS).  R47 is bent away from the RNA to accommodate the +1 
and +2 nucleotides.  C) The map obtained from particles with RNA, with +1 and +2 RNA 
fitted.  The contours for all the densities were set so that the levels in CPFS160 were as 




 Considering the particles classified without RNA (not in class 6), the  resulting map had a 
lower resolution (4.4 Å), and has many of the same features as the original map.  It has good 
density for CPSF160, CPSF30, and most of WDR33, but only has a large bulge around where A6 
of the PAS RNA would be (Fig 2.23A,B).  The section of WDR33 that is missing spans residues 
42-54 of WDR33, which are also missing in both the X-ray and cryo-EM structures of only 
WDR33 and CPSF160 (Clerici et al. 2017; Sun et al. 2017).  Presumably without the Hoogsteen 
base-pair of U3:A6 stacking with F43 (part of the RNA “clamp”), this segment of WDR33 
becomes disordered. 
Besides the missing RNA, the most prominent new feature seen in this EM-density map is 
a large bulge of density between zinc-finger 3 and WDR33, the origin of which is unknown (Fig 
2.23C).  Since only the particles with CPSF30 were kept prior to this analysis and during the 
structure determination of mPSF (174k, 38% of the total), perhaps what is seen is the very small 
population of mPSF with CPSF30 but not RNA (22k particles, 4% of the total, 13% of those with 
CPSF30).  In this case, the bulge could be from some other part of CPSF30 beyond zinc-finger 3 







Figure 2.24 Unexplained extra density is visible in the no-RNA density.  A)  The density 
in the same orientation as Figure 2.22.  B) CPSF30 has good density, although ZF3 may be 
slightly shifted.  C)  A side-view of the extra density, with WDR33 represented as a surface.  








 The studies outlined in this chapter provide an in-depth understanding of the way in which 
the mPSF complex specifically recognizes PAS-RNA.  The early experiments that tested the 
capacity of individual components of the complex were important in prompting the study of the 
assembled complex.  Using various methods, it was shown that each component, although having 
some ability to bind RNA, could not specifically bind the PAS.   
 The fluorescence polarization (FP) studies extended the previous studies, and provide 
additional details that highlight the importance the RNA length, residues of CPSF30, and PAS site 
sequence (Hamilton et al. 2019).  The binding mode observed in the structures was shown to be 
consistent for the most part with the FP results, save for the need for additional bases beyond the 
PAS (Sun et al. 2017; Clerici et al. 2018).  Reprocessing the EM data used for the initial structural 
studies to focus on the RNA provided some additional density that could explain this one 
inconsistency.  Although the residues identified as possibly interacting with the +2 base phosphate 
(R47 and K50) have been mutated as part of pairs to test the effect on RNA binding in a previous 
study (Clerici et al. 2017), it remains to be seen whether each by itself would change the affinity 






3 Structural and Biochemical Studies of the CPSF30—hFip1 Complex 
 
3.1 Introduction 
 As noted in previous chapters, the model of mPSF obtained by cryo-EM did not include 
hFip1 or the C-terminal region of CPSF30 (Sun et al. 2017; Clerici et al. 2018).  This is 
presumably because they don’t have a fixed orientation relative to the large CPSF160—WDR33, 
and their density is averaged out when the different particles are combined.  Despite this, the 
interaction between these two proteins is conserved from yeast to humans, and represents an 
important link connecting the PAS in the pre-mRNA and poly(A) polymerase (Zhao et al. 1999; 
Shi and Manley 2015; Sun et al. 2020). 
CPSF30 has five conserved zinc-fingers then a zinc knuckle, separated by a non-
conserved and putatively disordered region (Fig 2.1C).  The first zinc-finger stabilizes the 
interaction of CPSF30 with mPSF, and zinc-fingers 2-3 recognize and bind the AAUAAA 
sequence (Sun et al. 2017; Clerici et al. 2018).  The only known function of the remaining zinc-
fingers and zinc-knuckle are binding to hFip1 (Fig 3.1D) (Barabino et al. 1997; Kaufmann et al. 
2004).  hFip1 interacts with mPSF through this region of CPSF30 and tethers PAPα, allowing it 
to polyadenylate the cleaved mRNA (Fig 3.1B) (Meinke et al. 2008).   hFip1 may also 
participate in cleavage by binding to U-rich RNA regions through its C-terminal arginine-rich 
segment (Kaufmann et al. 2004), and by bridging the CFIm and CPSF complexes by interacting 
 
 78 
with the RS-domain of CFIm68 and CFIm59 though its own RS-domain (Fig 3.1A) (Zhu et al. 
2018).  These two interactions are involved in the selection of polyadenylation sites, making 
hFip1 an important regulator of APA.   
It has previously been observed that CPSF30 interacts with residues 137-243 of hFip1, 
but the structural basis of this was unknown (Kaufmann et al. 2004).  Here, we have crystallized 
and determined the structure of a human CPSF30—hFip1 complex, unexpectedly showing that 
two copies of hFip1 can bind to one copy of CPSF30.  We further validated that stoichiometry, 
and showed that mutations of each binding site on CPFS30 still allow hFip1 to bind, and that 
mutating both sites abrogates binding.  We then demonstrated that each site on CPSF30 is 





Figure 3.1 Multiple sequence alignments of CPSF30 and Fip1. (A) Alignment of Fip1, 
with the PAPα and Fip1 binding regions indicated.  (B)  Same alignment as A, but zoomed 
to show just the CPSF30-binding region.  The ends of the regions cloned are indicated with 
green arrows.  An α-helix predicted using PSIPRED is shown in pink (Buchan and Jones 
2019). (C)  Alignment of CPSF30, with the ends of the cloned regions shown with green 
arrows.  The zinc-fingers and zinc-knuckle are labeled.  D)  Same alignment as C, but 








3.2 Experimental Procedures 
3.2.1 Protein cloning, expression, and purification 
Human hFip1 (residues 159-200 or 79-200) and PAPα catalytic module (residues 1-524) 
were each cloned into a pET28a vector, in-frame with N-terminal His-tagged yeast SMT3 as a 
solubility tag.  Isoform 2 of human CPSF30 was used, which is missing 25 residues near the C-
terminus compared to the longest isoform.  It was cloned into a pET28a vector modified to be 
ampicillin resistant, either with no affinity tag (residues 114-173), or with an N-terminal His-
tagged yeast SMT3 (residues 62-244 or 1-244).  Mutations to CPSF30 and hFip1 were carried 
out following the QuikChange protocol (Agilent).  Human WDR33 was cloned into the MCS1 of 
pFL, in-frame with a TEV-cleavable His-tagged MBP.  CPSF160 was cloned into the MCS1 site 
of a separate pFL vector.  The pFL plasmids were inserted into the baculovirus bacmid using 
Tn7 recombination in DH10Bac cells (Thermofisher).  The bacmid was then transfected into Sf9 
cells using Cellfectin II (Gibco), and the resulting virus amplified. 
All expressions in E. coli were carried out using LB media with BL21(DE3) cells.  Each 
was induced with 0.5 mM IPTG and incubated at 17°C for 18h prior to harvesting using 
centrifugation.  The resulting cell pellets were flash-frozen and stored at -80°C until use. 
hFip1, PAPα, and CPSF30—hFip1 complexes were all purified using the same protocol, 
except that in samples with CPSF30, 100 µM ZnSO4 was added to all buffers, and those with 
full-length CPSF30 had at least 500 mM NaCl at all times.   First, the cells were lysed using 
sonication in buffer containing 50 mM Tris (pH 7.5), 200 mM NaCl, 30 mM imidazole, 10 mM 
beta-mercaptoethanol, and 2 mM PMSF. The lysate was centrifuged to clarify, then incubated 
with 5 mL Ni-NTA beads at 4°C.  The beads were then washed with two column-volumes of 
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buffer containing 2.5 M NaCl, then 3 column-volumes with 100 mM NaCl, and finally eluted 
with 10 mM buffer containing 100 mM NaCl and 250 mM imidazole.  100 µg UlpI protease was 
added to each elution and allowed to cleave overnight at 4°C.  After cleavage, the sample was 
run over a 5 mL Fastflow MonoQ column using a 100 mM to 2 M linear NaCl gradient over 15 
column-volumes.  Fractions were analyzed using SDS-PAGE, and the appropriate ones were 
purified further using a Superdex 200 16/60 column with a buffer containing 20 mM Tris (pH 
7.5), 100 mM NaCl, and 10 mM DTT.  CPSF30 alone was purified in the same manner as above, 
but with 50 mM arginine and at least 500 mM NaCl in the buffer during all steps. 
The CPSF160–WDR33 complexes were expressed using the Multibac system in High 
Five cells (Thermofisher) for 48h. The viruses were added in a 1:2.5 WDR33—CPSF160 ratio, 
since this was found to increase the yield of the complex.  The insect cells were lysed by 
sonication in a buffer containing 50 mM Tris (pH 8.0), 500 mM NaCl, 30 mM imidazole, 10 mM 
beta-mercaptoethanol, and one SIGMAFAST protease inhibitor cocktail tablet.  The lysate was 
mixed with 2 mL Ni-NTA beads (Qiagen), washed with 15 mL buffer containing 2 M NaCl to 
remove bound nucleic acids, then the protein was eluted with 5 mL buffer with 250 mM 
imidazole. 1 mg TEV protease was added, and the sample was incubated overnight at 4°C. It was 
then run over a Superdex200 16/60 column (GE Healthcare), using a buffer containing 20 mM 
Tris (pH 8.0), 350 mM NaCl, and 10 mM DTT. 
 
3.2.2 Crystallization of CPSF30—hFip1 complex 
Crystals of the CPSF30 (residues 62-173) and hFip1 (residues 159-200) complex were 
grown using sitting-drop vapor diffusion at 20°C in 3-well 96-well plate.  The complex was 
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concentrated to 21 mg/mL, and aliquoted onto the plate using a Mosquito liquid handler (SPT 
Labtech).  Crystals grew after ~2 months in a drop with a reservoir solution consisting of 0.1 M 
Sodium malonate (pH 4.0) and 12% w/v PEG 3350.  The crystals were picked and washed in the 
same buffer with 30% glycerol added, and frozen using liquid nitrogen. 
Crystals of the CPSF30 (residues 114-173) and hFip1 (residues 159-200) complex were 
obtained with 14 mg/mL protein using the sitting-drop vapor diffusion method at 20°C.  50 
µg/mL trypsin was added to the protein sample prior to set up, and the reservoir solution 
contained 0.1 M sodium malonate (pH 5.7) and 16% w/v PEG 3350.  Crystals were picked after 
2 months and flash-frozen with liquid nitrogen, using 30% glycerol as a cryo-protectant. 
 
3.2.3 Data collection and structure determination 
X-ray diffraction data was collected using the NE-CAT 24-ID-E beamline at the 
Advanced Photon Source.  The images were processed using XDS (Kabsch 2010), and the 
phases were determined using the CRANK2 pipeline in the CCP4 suite (Pannu et al. 2011), 
utilizing the anomalous scattering of the zinc atoms for SAD.  The structure was then rebuilt 
using COOT and refined with Refmac5 with TLS, iteratively (Emsley et al. 2010; Murshudov et 
al. 2011). 
 
3.2.4 FAM labeling of hFip1 
100 µM hFip1 (residues 159-200 or 137-234) mutated to only have one cysteine that was 
outside of the CPSF30 binding region (S159C/C189S or S159C/C189S/C216S) was mixed with 
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2 mM fluorescein-5-maleimide (Cayman Chemical Company) in a buffer consisting of 20 mM 
Tris (pH 7.5), 100 mM NaCl, and 1 mM TCEP. The reaction was allowed to proceed overnight 
at 4 °C in darkness. The next day, unreacted maleimide was rendered inactive by the addition of 
10 mM DTT. The fluorescein-labeled hFip1 was then purified using a Superose 12 10/300 
column (GE Healthcare). 
 
3.2.5 Fluorescence polarization assays 
Fluorescence polarization (FP) assays were performed on a Synergy Neo2 plate reader 
(Biotek) with polarizing filters (485 ± 20 nm excitation, 528 ± 20 nm emission).  The buffer 
contained 20 mM Tris (pH 7.5), 200 mM NaCl, 1 mM DTT, 0.03% NP-40, 0.1 µM BSA, and 5-
10 nM FAM-labeled hFip1.  Each titration was carried out in triplicate, and the results were 
analyzed using a locally developed Python program.   
 
3.2.6 Analytical gel filtration experiments 
50 µL of each sample was mixed and incubated on ice for 1h, then run on a Superose 12 
10/300 column.  The buffer contained 20 mM Tris (pH 7.5), 200 mM NaCl, and 10 mM DTT.  
The molecular weight of the eluted samples was calculated using a linear equation calibrated 






3.2.7 Polyadenylation reactions 
Assays were carried out following a modified version of a protocol detailed previously 
(Wahle 1995). All reactions were carried out in triplicate in a volume of 7.5 µL, using a buffer 
that consisted of 20 mM Tris (pH 8.0), 10% (v/v) glycerol, 150 mM NaCl, 5 mM MgCl2, 10 µM 
EDTA, 0.03% (v/v) NP-40, 10 mM DTT, 1 unit/reaction RNasin Plus RNase Inhibitor 
(Promega), 1 µM BSA (Sigma), and 1 µM PABPN1 (residues 45-296). The AAUAAA RNA 
primer is from the human adenovirus L3 polyadenylation site, with the sequence 
UUCAAUAAAGGCAAAUGUUUUUAUUUGUACA (or with the underlined segment replaced 
with AAGAAA). The reactions were heated at 30 °C for 5 minutes prior to addition of 1 mM 
ATP (Sigma), then allowed to react for 10 min at 30 °C prior to stopping with the addition of 7.5 
µL 2x stop buffer (40 mM Tris (pH 8.0), 8 M urea, 100 mM EDTA) and heating to 65 °C for 10 
min. The reactions were separated by running them on an 8% (w/v) acrylamide urea gel in TBE 
buffer, and then visualized using a Typhoon FLA 7000 (GE Healthcare). 
 
3.3 Results 
3.3.1 Purification of CPSF30—hFip1 complexes 
Various truncations of hFip1 were tested, starting with a fragment that was known to 
interact with CPSF30 (137-234) (Table 3.1).  Multiple sequence alignments of hFip1 were used 
to direct the truncations, with the shortest construct spanning only the most conserved region 
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(159-200). These were co-expressed with the various CPSF30 constructs that spanned zinc finger 
2 to the end (Table 3.1). 
Table 3.1 Constructs used for crystallization trials. 
CPSF30 
62-244 (ZF2 - C-terminus) 
62-216 (ZF2 - non-conserved region) 
62-173 (ZF2 - ZF5) 






As observed with CPSF30 alone, the samples were reddish when purified initially, but 
became clear after about one day if 100 µM ZnSO4 was included in all purification buffers.  The 
complexes behaved well otherwise, remaining stable even in salt as low as 50 mM NaCl (Fig 
3.2).  This is in contrast to CPSF30 alone, which needed 500 mM NaCl and 50 mM arginine 
added to the buffer to keep it from precipitating out of solution, suggesting that hFip1 binding 
blocks an aggregation-promoting region of CPSF30. 
 The complexes all eluted slightly earlier than expected from the gel filtration column, 
indicating that the stoichiometry of CPSF30 and hFip1 was possibly not 1:1.  To get a more 
accurate measurement of the apparent molecular weight, some of the complexes were run on a 





Figure 3.2  Representative purification of a CPSF30—hFip1 complex.  (A) SDS-PAGE 
gel showing the initial Ni-NTA purification (E), the cleavage with UlpI (Clv), and 
purification with a monoQ ion-exchange column.  (B) SDS-PAGE gel of the results of gel 
filtration (C) Profile of the gel filtration purification. 
 
3.3.2 Analytical Gel Filtration of CPSF30—hFip1 complexes 
 A small amount of some of the CPSF30—hFip1 complexes were run on a Superose 12 
column (Fig 3.3B).  Protein standards of known molecular weight (Biorad) were used to define a 
logarithmic curve of elution volume vs. molecular weight that could be used to estimate the size 
of the complex samples (Fig 3.3A). 
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 When the differences in observed versus expected molecular weights were tabulated, a 
trend was noticed (Table 3.2).  Complexes with the same hFip1 construct had approximately the 
same excess molecular weight, despite having different CPSF30 partners.  Two scenarios could 
explain this discrepancy:  either the hFip1 was elongated and appeared to have a larger molecular 








Figure 3.3 Analytical gel-filtration profiles of CPSF30—hFip1 complexes.  (A)  
Calibration curve of the Superose 12 column.  (B) Overlaid gel-filtration profiles of the 
CPSF30—hFip1 complexes. 
 
Table 3.2 Analytical gel-filtration results of CPSF30—hFip1 complexes 
  
Elution 







CPSF30-62-244   + hFip1-137-200 12.2 28.3 41.2 12.9 7.3 
CPSF30-62-173   + hFip1-137-200 12.5 20.6 32.5 11.9 7.3 
CPSF30-62-244   + hFip1-159-200 12.7 26.1 29.9 3.8 5.1 




3.3.4 Crystallization and solving the structure of the CPSF30—hFip1 complex 
 Purified samples of the CPSF30—hFip1 complex were used to set up crystallization 
screens with ~1000 buffer conditions each.  Various combinations of the truncations of either 
protein were used, but no crystals were observed within the first month.  It was only after almost 
two months that crystals grew, and only in one condition with a single CPSF30—hFip1 
combination (Fig 3.4).  The CPSF30 spanned zinc fingers 2 to 5 (res. 62-173), and the hFip1 
construct was the smallest tested (res. 159-200).  The crystals were small (< 0.05 millimeter) and 
mostly were clusters of needles, but three were thicker prisms which were picked and frozen in 
liquid nitrogen (Figure 3.4).  These crystals were then examined at the NECAT-ID-E beamline at 






Figure 3.4 Vapor-diffusion crystallization drop with initial crystal hit.  The usable crystals 
are indicated with blue arrows, and a fungal growth by a green arrow. 
 
 Because there was no homologous structure for molecular replacement, it was hoped that 
single-wavelength anomalous diffraction (SAD) could be used to obtain the phases needed to 
solve the structure.  The x-ray wavelength at the beamline used could not be changed (0.979 Å):  
it was set to be just short of the K-edge of selenium.  This was much shorter than the K-edge for 
Zn (1.283 Å), but it was possible that the four zinc atoms in CPSF30 would provide enough 
anomalous signal to calculate phases for the structure factors, when combined with methods such 
as density modification. 
 One of the crystals diffracted to 2.8 Å, and was indexed to the space-group P64 with the 
unit cell dimensions a=b=79.0 Å, c=48.7 Å.  Using these parameters, the solvent content of 
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different stoichiometries of CPSF30—hFip1 could be estimated.  If they existed in a 1:1 ratio, 
the solvent content was estimated to be 50%, and if it was 1:2 the solvent content was 36%.  
Therefore, the possibility of more than one Fip1 was low with this construct of CPSF30 (zinc-
fingers 2 to 5), since few crystals have a solvent content as low as 36%. 
An anomalous signal was found, but it was weak and didn’t extend beyond ~6 Å.  
Despite this, phasing was attempted using the CRANK2 pipeline of CCP4 (Ness et al. 2004).  It 
found a substructure of the anomalous scatterers using the SHELXD program (Schneider and 
Sheldrick 2002), but instead of the expected 4 it found only 2 sites with occupancies greater than 
25%.  This meant that either two of the zinc-fingers were somehow removed during 
crystallization, or were so flexible within the crystal lattice that their signal was averaged out.  
Following refinement of the two zinc sites with REFMAC5 and solvent flattening using 
PARROT (Cowtan 2010), the pipeline failed when it attempted to build a structure into the 
resulting density(Fig 3.5).  There were some poly-alanine chains built in, but the connections 
between them were so ambiguous and the sidechain density so poor that determining which part 
came from which molecule was infeasible. 
 Despite the lack of success building a structure, examining the solvent-flattened density 
was informative and helped to guide the next steps taken.  Most importantly, there was not 
enough space in the crystal lattice for the other two zinc-fingers, so they must have been cleaved 
off during the crystallization.  It was assumed that the remaining zinc-fingers were 4 and 5, since 
they were known to bind hFip1.  One α-helix of ~15 residues was clearly seen, which was 
thought to perhaps be a helix from hFip1 (res. 182-197) that was predicted using the PSIPRED 
server (Jones 1999).  This would seem to lay to rest the notion that there were more than one 
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hFip1 molecules per CPSF30, since there was only one such long α-helix.  The only other 




Figure 3.5 Segmented contiguous density obtained from phasing the first CPSF30—
hFip1 crystal using the weak anomalous signal.  The largest contiguous region that 
contained both zinc sites was extracted from the electron density using the Segger in UCSF 
Chimera (Pettersen et al. 2004; Pintilie et al. 2010), and the isosurface at 1 r.m.s.d. was 
displayed.  The two large blobs that contain the zincs (purple spheres) were identified as 
zinc-fingers.  An α-helix is clearly visible lying between the two zinc fingers, with a possible 
shorter one turned ~90°. 
 
Given the removal of two zinc-fingers during crystallization, it was suspected that there 
may be some protease present in the buffer.  Cleavage in the crystallization drop by a fungal 
protease has been previously observed in our lab (Mandel et al. 2006; Bai, Auperin, and Tong 
2007), so it wasn’t unexpected that a fluffy growth was observed in a picture of the initial drop 
(Fig 3.4).  It seemed to be a chance thing, since no other drops using this condition and other 
complexes had a fungal growth (such are the vagaries of crystallography). 
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New crystallization drops were set up, using two truncations of CPSF30 (either zinc-
fingers 2 - 5, or just 4 - 5) and hFip1 (res. 159-200).  Added to the drops were dilutions of one of 
three proteases: trypsin, chymotrypsin or subtilisin.  Amazingly, in some drops with CPSF30 
zinc-fingers 4-5 and added trypsin (1:150 weight ratio), crystals grew after a few days.  After 
optimizing the buffer conditions, crystals could be grown to a larger size overnight reliably (Fig 
3.6).  The crystals continued to grow slowly over time, so some were left to grow for 55 days 








Figure 3.6 Overnight growth of CPSF30—hFip1 crystals in a buffer containing 1:150 
w/w trypsin.  The crystals were much larger than those previously obtained.  The rainbow 
coloring is due to a polarizing filter. 
 
 These new crystals were shot at the same synchrotron as the previous set, and one 
diffracted to 1.9 Å resolution with the same lattice as before (P64; a=b=79.0 Å, c=48.7 Å).  
When processed with XDS, the signal-to-noise of the new dataset was much higher than the 
previous one, even at the same resolution (50.3 vs. 2.2 at 3 Å).  Unsurprisingly, the anomalous 
signal was stronger this time, and phasing with SAD was straightforward using the CRANK2 
pipeline.  The model was built automatically with BUCCANEER (Cowtan 2006), and a 
surprising result was obtained.  Despite only having the one long α-helix, two copies of hFip1 
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were found in the asymmetric unit, with the second one truncated in the middle of its helix (Fig 
3.7A). 
 The truncations explained why the previous observations from the first crystal that 
seemed to refute a 1:2 CPSF30—hFip1 stoichiometry didn’t actually do so.  First, the solvent 
content of a 1:2 complex wasn’t 35%, since two of CPSF30’s zinc-fingers were removed: it was 
estimated to be 67% without them, a perfectly acceptable value.  Second, only one long α-helix 
was observed in the solvent-flattened density because the second one was shortened by 
proteolysis. 
 
3.3.5 Structure of the CPSF30—hFip1 complex 
 The structure has zinc-fingers 4-5 of CPSF30 and two copies of hFip1 (hFip1-A and 
hFip1-B, Fig 3.7A).  The two zinc-fingers are approximately orientated orthogonally and flipped 
in relation to each other, with the C-terminal portion of zinc-finger 4 (ZF4) crossing the C-
terminal of zinc-finger 5 (ZF5) at ~90° (Fig 3.7B).  hFip1 consists of a loop region (residues 
162-181) and an alpha helix (residues 182-199).  The loop region of hFip1-A interacts with ZF4 
of CPSF30 and its helix interacts with ZF4, the C-terminal region of ZF5, and the coiled region 
hFip1-B.  The hFip1-B loop region interacts with ZF5 of CPSF30 in much the same manner as 
hFip1-A with ZF4, but as mentioned above it also interacts with the helix of hFip1-A instead of a 
C-terminal region of a zinc-finger.  The helix of hFip1-B is cleaved after K191, so it is 






Figure 3.7 Structure of the CPSF30—hFip1 complex.  A) The structure consists of two 
copies of hFip1, each bound to a zinc-finger.  The second hFip1 copy (hFip1-B) has no 
electron density beyond residue K191.  B)  CPSF30-ZF4—hFip1-A is flipped ~180° and 
rotated ~90° compared to CPSF30-ZF4—hFip1-B.  When those rotations are performed on 





Table 3.1 Summary of crystallographic information 
Data Collection    
Space group P64 
Cell dimensions   
a, b, c (Å) 79.0, 79.0, 48.7 
α, β, γ  (º) 90, 90, 120 
Resolution (Å)1 48.7-1.9 (1.94-1.90) 
Rmerge (%) 3.8 (83.0) 
CC1/2 1.000 (0.788) 
I/σI 30.9 (3.1) 
Completeness (%) 100.0 (99.9) 
No. of reflections 13793 (869) 
Redundancy 12.6 (10.9) 
Refinement    
Resolution (Å) 39.6-1.9 (1.95-1.90) 
Rwork (%) 18.1 (26.2) 
Rfree (%) 20.9 (24.9) 








r.m.s.d.   
Bond lengths (Å) 0.017 
Bond angles (°) 2 
 Ramachandran plot   
Favored (%) 96.6 
Allowed (%) 100 
Outliers (%) 0 




Overlaying the two zinc-fingers and hFip1s show that the interacting pairs share a very 
similar structure, with a nearly identical interface with their respective hFip1s (Fig 3.8).  A 
tyrosine in both zinc-fingers (Y127 in ZF4, and Y151 in ZF5) each hydrogen bond with the 
carbonyl of S173 on their respective hFip1s.  The histidine that coordinates the zinc in each zinc-
finger (H142 or H166) is hydrogen-bonded to the main-chain carbonyls of D174 from each 
hFip1, while the side-chains of the D174 interact with the sidechains of R144 in ZF4 and R168 
in ZF5.  The phenolic hydroxyl of Y178 in each hFip1 also forms a hydrogen bond with the 
main-chain carbonyl of D128 in ZF4 and L152 in ZF5.  Finally, there are also two hydrogen 
bonds formed between the main chains of CPSF30 and hFip1.  First, the carbonyl of Y175 
interacts with the amino group of one of the cysteines that coordinates each zinc: C132 in ZF4 
and C156 in ZF5.  Second, the amino group of N177 in each hFip1 hydrogen bonds with either 
G130 in ZF4 or G154 in ZF5. 
Looking at R144 in ZF4 and R168 in ZF5 reveals a difference between the two 
interactions:  although the guanidine group from each is in the same position relative to hFip1, 
each main chain is in very different positions (Fig 3.8D).  In ZF4, the main chain is curled 
around hFip1-A, allowing the main-chain amino group of R145 to hydrogen-bond with the side-
chain of N177 in the hFip1.  By contrast, in ZF5 the main chain is rotated out 23.5° to 
accommodate hFip1-A, allowing F169 (the residue equivalent to R145) to pack against the side 
of it. 
As noted previously, the helix of hFip1-A interacts with not only CPSF30 but also the 
loop region of hFip1-B giving rise to ~300 Å2 buried surface area.  This is comparable to the 
surface area buried by the ZF5—hFip1-B interaction (480 Å2), although it is much less than that 
from the ZF4—hFip1-A interaction (750 Å2).  Yet this hFip1-A—hFip1-B interaction doesn’t 
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seem to change the way each interacts with CPSF30.  Surprisingly, there is no point at which all 
three proteins come in contact which each other, although there are three buried waters that 
bridge them (Fig 3.9A).  These waters are well-ordered, with B-factors ranging from 33-35 Å2, 
comparable to the surrounding protein.  These waters are coordinated by the sidechains of Q192 
and Y188 from hFip1-A and N177 from hFip1-B, and the CPSF30 main-chain carbonyls from 







Figure 3.8  hFip1 binds to zinc-fingers 4 and 5 in an almost identical manner.  A)  
CPSF30-ZF4— hFip1-A.  Residues important to the interaction are shown as sticks, and 
interactions between the two are shown as dashes.  B)  CPSF30-ZF5— hFip1-B, with hFip1 
in the same orientation as in (A).  C)  The two zinc-finger: hFip1s overlaid.  Orientations 
and coloring are the same as (A) and (B), except that ZF5 is in grey.  D)  Two copies of 
CPSF30 overlaid with one hFip1 shown, to illustrate why the protein adopts a different 
conformation C-terminal to each zinc-finger.  It can be seen that the segment in ZF5 is 





Figure 3.9 Buried waters help to bridge CPSF30, hFip1-A, and hFip1-B.  A)  Three buried 
waters are shown as spheres, and CPSF30 (green) and hFip1-A (orange) are shown as 
surfaces.  hFip1-B (blue) is shown as a cartoon for visibility.  B)  Coordination of the three 
waters by all three proteins.  The electron density of the waters is shown as a mesh at a 1σ 
2Fo-Fc contour. 
 
 Examining the crystal packing of the complex reveals why the samples without added 
protease failed to crystallize.  If the helix of hFip1-B is not cleaved after K191, it would overlap 
with the ZF5 of a CPSF30 in an adjacent asymmetric unit (Fig 3.10B).  The cleavage site on 
hFip1-A was presumably protected from trypsin by its interaction with CPSF30.   
The cleavage of CPSF30 prior to I121 also allows the packing against another complex in 
the neighboring asymmetric unit (Fig 3.10A).  The cleavage site is in between zinc-fingers 3 and 
4, of which only the former was observed in the mPSF structures (Clerici et al. 2018; Sun et al. 
2018).  Presumably, the region between the two is not ordered to allow access by trypsin.  This 
supports the notion that CPSF30 zinc-fingers 4-5 and hFip1s were averaged out in those 
structures because they are not in a stable orientation with respect to the rest of the mPSF, due to 





Figure 3.10 Cleavage of CPSF30 and hFip1-B facilitates crystal packing.  Electron 
densities from the CPSF30—hFip1 crystal overlaid with the fitted model.  All 2Fo-Fc 
densities are shown as mesh at 1σ level at 1.9 Å resolution. A)  The lack of density and space 
for more residues shows that cleavage occurs prior I121 of CPSF30 (green).  The hFip1-B’s 
from neighboring asymmetric units are colored light blue.  B)  The same as (A), but instead 
showing the cleavage after K191 of hFip1-B (blue).  Interestingly, both cleaved chains are 
next to each other in the crystal structure. 
 
Comparison to the other zinc-fingers of CPSF30 observed in the cryo-EM structure of 
mPSF bound to RNA show a remarkable similarity in structure, although they lack critical 
residues in the hFip1 interface (Fig 3.11A,B).  Looking at it from the other side, zinc-fingers 4 
and 5 could not bind to an AA-dinucleotide like zinc-fingers 2 and 3.  This is because each zinc-
finger has a proline at a critical position: P125 in ZF4 blocks binding with N1 of the first 
adenosine in the dinucleotide, and P157 in ZF5 blocks binding of the N1 of the second adenosine 
(Fig 3.12A,B) .  In fact, each set of zinc-fingers utilizes a different face to bind its partner(s).  
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Zinc-finger 1 uses its “bottom” surface to the N-terminus of CPSF30 and β-propeller-C of 
CPSF160, zinc-fingers 2 and 3 uses their “back” surface to bind to the AA-dinucelotide, and 
zinc-fingers 4 and 5 use their “top” surface to bind to hFip1 (Fig 3.11C-G). 
 
 
Figure 3.11 Comparison of the binding modes of all the CPSF30 zinc-fingers shows 
divergent interaction surfaces.  A)  Alignments of the human ZCPSF30 zinc-fingers.  
Highlighted in blue are the zinc-coordinating residues, green those critical to hFip1 biding, 
and pink the prolines that block AA-dinucleotide binding.  B) Overlay of the 5 zinc-fingers 
from CPSF30. C-F) Zinc-fingers 1-5 in the same orientation as (A), with each of their 






Figure 3.12 Prolines 125 in zinc-finger 4 and 157 in zinc-finger 5 prevent AA-RNA 
binding. A)  Zinc-fingers 2 (orange) overlaid with zinc-finger 4 (blue), and adenosine 1 of 
the PAS RNA (green).  P125 in ZF4 blocks the interaction of N1 of the adenosine with the 
main-chain of K69 in ZF2 (shown as a dotted yellow line).  B)  Same as (A), but this time 
showing zinc-finger 5 (cyan) and adenosine 2 of the PAS RNA.  P157 now blocks the same 








3.3.6 Analytical gel filtration of the CPSF30—hFip1 complex using CPSF30 mutants 
The stoichiometry of the subunits in the crystal structure raises a question: is this a real 
interaction, or just an artifact of crystal packing?  If there were two hFip1 proteins per mPSF, 
there could be effects on polyadenylation site selection and PAPα recruitment.  It could mean 
that the hFip1s could bind multiple poly-U regions, or interact with two copies of CFIm25—
59/68.  It is notable that the functional unit of the latter has two copies (Yang et al. 2010; Yang et 
al. 2011). 
To test whether the 1:2 CPSF30—hFip1 complex could be observed in solution, a series 
of size-exclusion chromatography experiments were carried out.  These involved mixing 
CPSF30 (zinc-finger 2 to the end) with three times excess hFip1 (res. 159-200) in order to 
evaluate the size of the resulting complex.  This construct of CPSF30 was used because the 
solubility of zinc-fingers 4-5 alone was extremely low.  In addition, to evaluate whether both 
sites on CPSF30 are competent for hFip1 binding, a series of mutations was carried out: the two 
tyrosines in CSPSF30 (Y127, Y151) observed to be central to hFip1 binding were mutated alone 
or together to alanine.   
When wild-type CPSF30 was mixed with an excess of hFip1, the position of the complex 
peak was what was expected for a 1:2 CPSF30—hFip1 stoichiometry, and both proteins could be 
seen in the SDS-PAGE gel (Fig 3.13, Table 3.2).  When the double mutant (Y127A/Y151A) was 
mixed with hFip1, the peak was at the correct volume for CPSF30 alone, and hFip1 was not 
observed in the gel, confirming that the selected mutations effectively disrupt hFip1 binding.  For 
both single mutants, the peak elution volume corresponded to the size of 1:1 CPSF30—hFip1, 







Figure 3.13 Analytical gel-filtration of CPSF30 mutants with hFip1 shows that the 
expected stoichiometry.  The chromatograms from the gel-filtrations (left) show that each 
mutation can still bind to one copy of hFip1, and that wild-type can bind two copies.  The 
SDS-PAGE gel (right) confirms that the double-mutant shifts no hFip1 to its peak volume, 
while the single-mutants and the wild-type do. 
 








CPSF30-WT + hFip1 1:2 31.1 12.0 32.4 
CPSF30-Y127A + hFip1 1:1 26.0 12.3 27.0 
CPSF30-Y151A + hFip1 1:1 26.0 12.3 27.0 
CPSF30-Y127A-Y151A + hFip1 1:0 21.0 12.7 21.0 




3.3.7 Fluorescence polarization assays of CPSF30—hFip1 complex formation 
 Although we demonstrated that hFip1 binds to each site on CPSF30, it wasn’t clear 
whether it was an artifact of the high concentrations used, and if the Kd of each site is low 
enough to be physiologically relevant.  To test this, FAM-maleimide was reacted with a mutant 
of hFip1 which had its cysteines mutated to serines, and a serine shown to be disordered in the 
structure to cysteine (S159C).  This labeled product was titrated against CPSF30 (residues 62-
244), and the fluorescence polarization was measured.   
 The results show that the sites on both zinc-fingers 4 and 5 can bind hFip1 in the 
nanomolar range (Fig 3.14).  As is expected given the much larger binding interface ZF4 
(Y151A mutant) binds much more strongly than ZF5 (Y127A mutant).  These ranges of Kd 
values make it possible that the observed stoichiometry is correct, and that two hFip1s are indeed 
in each mPSF complex.  This does not necessarily mean that each are active and participate in 
the known functions of hFip1, so further characterization was carried out to test this.  The double 









Figure 3.14 Fluorescence polarization anisotropy of a titration of CPSF30 shows that 
each zinc-finger binds to hFip1 with a nanomolar Kd.  Titrations of each CPSF30 into 
solutions containing either residues 159-200 (red) or 137-234 (blue) of FAM-labeled hFip1 
are shown.  It can be seen that both single-mutants and the wild-type bind to hFip1, while 
the double mutant does not.   ZF5 (Y127A mutant) binds with a lower affinity compared to 
ZF4 (Y151A mutant). 
 
3.3.8 Analytical gel filtration of the CPSF30—hFip1—PAPα complex 
These results demonstrated that the stoichiometry was indeed 1:2 for the wild-type in 
solution, and that each site could indeed bind hFip1 on its own.  But they did not prove that the 
two hFip1s were both competent to carry out its functions such as the binding of PAPα.  To 
check if they could, a pre-formed CPSF30—hFip1 complex was mixed with a PAPα construct 
(residues 1-524) that has previously been shown to be competent for polyadenylation and hFip1 
binding in vitro (Martin and Keller 1996; Kerwitz et al. 2003).  The hFip1 construct used was 
longer (residues 79-200), to include the region observed to bind PAPα, and the CPSF30 was full-
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length.  The double-mutant CPSF30 was not used, since it was not stable and not enough sample 
could be purified for this assay.  Presumably without hFip1-binding to help its stability it 
aggregates like other truncations of CPSF30 (see chapter 2). 
The results demonstrated that two copies of PAPα bind to the wild-type CPSF30—hFip1 
complex, and one copy to the single-site mutants (Fig 3.15, Table 3.3).  hFip1s bound to each 
site on CPSF30 are still competent on their own to tether PAPα, raising the possibility that two 
PAPα molecules are brought to each polyadenylation reaction.  In order to test whether each 








Figure 3.15 Analytical gel filtration of CPSF30—hFip1— PAPα complexes shows that 
each hFip1-binding site is competent to tether PAPα.  The chromatograms from the gel-
filtrations (left) show that each CPSF30 mutant can still bind to one PAPα through hFip1, 
and that the wild-type can bind two PAPαs.  The SDS-PAGE gel (right) shows PAPα is 
shifted to the volume of each peak in all the gel-filtration runs. 
 
Table 3.3 Analytical gel filtration results using the CPSF30—hFip1—PAPα complex. 








CPSF30-WT + hFip1 + PAPα 1:2:2 174.6 9.3 160.8 
CPSF30-Y127A + hFip1 + PAPα 1:1:1 101.0 10.0 106.2 







3.3.9 Polyadenylation Reactions 
 To test whether the CPSF30—hFip1—PAPα complex could bind to the rest of mPSF 
(CPSF160 and WDR33) and promote polyadenylation, reactions using FAM-labeled PAS-RNA 
primer were carried out.  Furthermore, to test if the polyadenylation was indeed due to tethering 
PAPα to mPSF, a mutant FAM-labeled PAS-RNA primer was used that should not be able to 
bind to mPSF with a high affinity like the wild-type PAS (see chapter 2 for quantitative analysis 
of the affinities).  As a positive control Mn+2 was added to reaction with no CPSF30 or hFip1.  
This metal has been shown to increase the activity of PAPα to the extent that it doesn’t require 
tethering to mPSF to carry out polyadenylation on any RNA substrate (Takagaki et al. 1988; 
Martin et al. 2004).   
 The results of these reactions demonstrate that each hFip1 binding site on CPSF30 can 
tether PAPα to the mPSF—RNA complex in a productive fashion (Fig 3.16).  It isn’t known 
whether two copies of PAPα change the kinetics of polyadenylation, since this assay is not 
sensitive to show small differences in activity.  In fact, all three repeats gave slightly different 






Figure 3.16 Polyadenylation reactions using the CPSF30 mutants. These reactions show 
that each hFip1 binding site is competent to promote complex formation competent for the 
addition of a poly-adenosine to each PAS-RNA primer, just like the wild-type CPSF30.  
Samples with no CPSF30 and/or a mutated PAS-RNA show no polyadenylation.  Samples 
with Mn+2 show non-specific polyadenylation. 
 
3.4 Discussion 
 These studies, in combination with previously published research, have determined the 
molecular basis for the function of each zinc-finger in CPSF30 (Sun et al. 2017; Clerici et al. 
2018).  All the zinc-fingers resemble each other, but each belong to a different functional type:  
zinc-finger 1 binds to the N-terminus of CPSF30 and CPSF160, zinc-fingers 2 and 3 each bind to 
the AA-dinucleotides of the PAS-RNA, and zinc-fingers 4 and 5 each bind a copy of hFip1. 
The unexpected 1:2 stoichiometry of hFip1 to mPSF is mediated through zinc-fingers 4 
and 5 of its CPSF30 subunit, with each zinc-finger binding one hFip1.  The Kd’s of each 
interaction were determined, showing that both bind in the nanomolar range, although zinc-
finger 4 binds more tightly (~ 1nM). 
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The residues that mediate this interaction are highly conserved in both proteins from 
yeast to humans, indicating that this is a conserved mechanism through eukaryotes (Fig. 3.17).  
Previous observations in yeast had even supported the presence of two copies of Fip1 and PAP in 
the polyadenylation complex, although the mechanism of this was not speculated on (Casañal et 
al. 2017).  In that study, mass-spectrometry pull-down assays observed a 2:1 stoichiometry of 
Fip1—PAP to Cft1—Pfs2—Yth1 (yeast homologs of hFip1—PAPα and CPSF73—WDR33—
CPSF30).  Interestingly, they also observed two copies of Fip1 in the complex with one copy of 
PAP, but not two copies of PAP and one of Fip1.  This supports the mechanism of the 
recruitment of each of the two PAPs through two Fip1 molecules. 
 
 
Figure 3.17 The CPSF30—Fip1 interaction surfaces are conserved between yeast and 
humans. (A)  Alignment of zinc-fingers 4-5 from yeast Yth1 and human CPSF30.  The 
coloring is red: identical residues, pink: similar residues, white: not conserved.  (B) 
Alignment of the yeast and human CPSF30-interacting regions of Fip1, with the loop region 
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and α-helix observed in the human structure annotated.  The coloring is the same as in (A).  
(C)  The structure of the human CPSF30—hFip1 complex, with the residues colored as in 
(A-B).  CPSF30 is shown as a surface, and the hFip1 molecules are shown as cartoons.  It 
can be seen that the regions in of the molecules that contact another are highly conserved, 
while those regions that do not tend to be less conserved. 
 
In mammals and other higher organisms, the 2:1 stoichiometry plays into a common motif of 
dimers of RNA-interacting complexes in the RNA 3’-end processing machinery: both CstF and 
CFIm are dimers (Bai, Auperin, Chou, et al. 2007; Legrand et al. 2007; Yang et al. 2011).  hFip1 
has been shown to interact with both of these complexes (Kaufmann et al. 2004; Zhu et al. 2018), 
giving a possible way that two RNA-binding events from each can be integrated with mPSF 
binding the single PAS in the RNA.  Each dimer of the two complexes could bind two hFip1s, 
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Biophysical characterizations of the recognition
of the AAUAAA polyadenylation signal
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ABSTRACT
Most eukaryotic messenger RNA precursors must undergo 3′ -end cleavage and polyadenylation for maturation. We and
others recently reported the structure of the AAUAAA polyadenylation signal (PAS) in complex with the protein factors
CPSF-30, WDR33, and CPSF-160, revealing the molecular mechanism for this recognition. Here we have characterized
in detail the interactions between the PAS RNA and the protein factors using fluorescence polarization experiments.
Our studies show that AAUAAA is recognized with ∼3 nM affinity by the CPSF-160–WDR33–CPSF-30 ternary complex.
Variations in the RNA sequence can greatly reduce the affinity. Similarly, mutations of CPSF-30 residues that have van
derWaals interactions with the bases of AAUAAA also lead to substantial reductions in affinity. Finally, our studies confirm
that both CPSF-30 and WDR33 are required for high-affinity binding of the PAS RNA, while these two proteins alone and
their binary complexes with CPSF-160 have much lower affinity for the RNA.
Keywords: RNA processing; RNA recognition; protein structure
INTRODUCTION
Most eukaryotic messenger RNA precursors (pre-mRNAs)
must undergo extensive processing to become functional
mRNAs, which includes 5′-end capping, splicing, and 3′-
end cleavage and polyadenylation (Proudfoot 2011;
Yang and Doublié 2011; Curinha et al. 2014; Xiang et al.
2014; Shi andManley 2015). The recognition of a polyade-
nylation signal (PAS) is a crucial step for 3′-end processing,
which helps to define the position of cleavage in the pre-
mRNA as the PAS is often located 10–30 nt upstream of
the cleavage site. The PAS is a hexanucleotide, and the
most common motif is AAUAAA (∼55% frequency) for
mammalian pre-mRNAs, followed by the AUUAAA motif
(∼16% frequency) (Proudfoot and Brownlee 1976;
Beaudoing et al. 2000; Tian et al. 2005). Many other motifs
can also support 3′-end processing, but are much rarer
(<4% frequency). AAUAAA, AUUAAA, and 10 other single
nucleotide variants account for∼92% of PAS in human and
mouse pre-mRNAs (Tian et al. 2005).
Many proteins are involved in pre-mRNA 3′-end pro-
cessing (Zhao et al. 1999; Mandel et al. 2008; Shi et al.
2009), and several subcomplexes of this 3′-end processing
machinery have been identified, including the cleavage
and polyadenylation specificity factor (CPSF) and the
cleavage stimulation factor (CstF). The 73-kDa subunit of
CPSF (CPSF-73) is the endoribonuclease for the cleavage
reaction (Mandel et al. 2006), and two other CPSF sub-
units, WDR33 (Shi et al. 2009) and CPSF-30, are required
for recognizing the PAS (Chan et al. 2014; Schönemann
et al. 2014). CPSF-30, containing five zinc fingers and a
zinc knuckle, also interacts with Fip1 (Kaufmann et al.
2004), another subunit of CPSF, which helps to recruit
the poly(A) polymerase to the 3′-end processing machin-
ery. CstF recognizes a G/U-rich sequence motif down-
stream from the cleavage site, and it also has a role in
alternative polyadenylation (Elkon et al. 2013; Gruber
et al. 2014; Tian and Manley 2017).
We and others recently reported the structures of a qua-
ternary complex of human CPSF-160, CPSF-30, WDR33,
and an AAUAAA PAS RNA (Fig. 1A,B; Clerici et al. 2018;
Sun et al. 2018), the structure of a ternary complex of the
yeast protein homologs (Cft1, Yth1, and Pfs2, without
RNA) (Casañal et al. 2017), as well as the structure of a bi-
nary complex of human CPSF-160 and WDR33 (Clerici
et al. 2017). The structures of the quaternary complexes
revealed extensive and specific interactions between the
AAUAAA PAS and WDR33 and CPSF-30 (Fig. 1C), while
CPSF-160 serves a crucial scaffold role in the complex. In
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addition, there is a Hoogsteen base pair between U3 and
A6 of the PAS. A few aspects of the interactions between
the ternary complex and PAS RNA have been studied by
fluorescence polarization assays (Clerici et al. 2017), in-
cluding Kd values for RNAs containing AAUAAA and
AAGAAA PAS, the contributions of different CPSF-30
zinc fingers to RNA binding, and the effects of two muta-
tions in WDR33 (K46A/R47A and R49A/K50A) on RNA
binding. We had also characterized the interactions
among the protein factors and the RNA by gel shift assays
(Sun et al. 2018).
We report here detailed characterizations of the interac-
tions between CPSF-160, WDR33, CPSF-30, and various
PAS RNAs. We show that the ternary complex has high af-
finity for the AAUAAA PAS RNA, with Kd of ∼3 nM, and the
AUUAAA PAS RNA has a Kd of ∼17 nM. In comparison,
other sequence motifs that can also support 3′-end pro-
cessing, as well as changes to the U3–A6 Hoogsteen
base pair, lead to a substantial reduction in the binding af-
finity. In addition, mutations of CPSF-30 residues that are
in contact with the RNA bases can also give rise to reduc-
tions in binding affinity. The CPSF-160–WDR33 and CPSF-
160–CPSF-30 binary complexes have much lower affinity
for the RNA, confirming that both WDR33 and CPSF-30
are required for PAS recognition. We also show that
CPSF-160 is required for high-affinity recognition of the
PAS RNA, as WDR33 and CPSF-30 alone have much lower
affinity.
RESULTS
Variation of the AAUAAA RNA length
The structures of the quaternary complexes show that
WDR33 and CPSF-30 primarily recognize the PAS hexanu-
cleotide itself (Fig. 1C). Although a 17-mer RNA was used
for the structural study, only the PAS was found to be well
ordered (Sun et al. 2018). The nucleotide directly following
the PAS was weakly ordered, and the other nucleotides
were disordered. To assess this structural observation, we
used RNA oligos of various lengths, 17-mer (FAM-AACC
UCCAAUAAACAAC), 11-mer (FAM-CAAUAAACAAC) and
6-mer (AAUAAA-FAM), and carried out fluorescence polar-
ization binding assays. All these oligo RNAs carry a FAM
fluorescent label at the 5′ or 3′ end, allowing direct obser-
vation of the fluorescence polarization signal.
The experimental data confirmed that the 17-mer and
11-mer RNAs have nearly the same binding affinity to
the CPSF-160–WDR33–CPSF-30 ternary complex, with
Kd values of 0.28±0.07 nM and 0.32±0.04 nM (P value
of 0.34, and therefore the difference is not significant), re-
spectively (Table 1; Fig. 2A), consistent with that reported
in an earlier study (Clerici et al. 2017). Fip1 (residues 159–
200) was included in these experiments to help stabilize
full-length CPSF-30. Without Fip1, the Kd value for the
17-mer RNA decreased slightly to 0.25±0.05 nM (P value
0.24) (Table 1; Fig. 2A), suggesting that Fip1 has essential-
ly no effect on binding this 17-mer RNA. Earlier studies
have shown that this segment of Fip1 is involved in binding
CPSF-30, while a carboxy-terminal Arg-rich region of Fip1
(missing in the protein studied here) interacts with U-rich
RNA (Kaufmann et al. 2004).
In comparison, the 6-mer oligo had a higher Kd value of
8.05±0.45 nM (P value <0.001). This could be due to inter-
ference by the FAM label at its 3′ end and/or contribution
from nucleotides outside the PAS. For example, the phos-
phate group of the nucleotide directly following the PAS
has some interactions with WDR33 (Fig. 1C). To assess
these different scenarios, we used unlabeled AAUAAA
6-mer oligo, AAUAAAC 7-mer oligo, and CAAUAAAC
FIGURE 1. Overall structure of the human CPSF-160–WDR33–CPSF-
30–PAS RNA quaternary complex. (A) Structure of the quaternary
complex. CPSF-160 (yellow), WDR33 (blue), and CPSF-30 (green)
are shown as molecular surfaces. The PAS RNA is shown as a sphere
model (orange). (B) Structure of the quaternary complex, viewed after
a 90° rotation of around the vertical axis. (C ) Recognition of the
AAUAAA PAS (orange) by CPSF-30 zinc fingers ZF2-ZF3 (green) and
WDR33 (blue). Hydrogen bonds in the U3–A6 Hoogsteen base pair
are indicated with dashed lines in red. Side chains of CPSF-30 that
contact the RNA bases are shown as stick models, and those selected
for mutagenesis studies are labeled in red. Zinc atoms are shown as
spheres in pink. Produced with PyMOL (www.pymol.org).
Hamilton et al.
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8-mer oligo and carried out competition fluorescence po-
larization binding assays against the FAM-labeled 17-mer
oligo (Fig. 2B). We included the unlabeled 11-mer
CAAUAAACAAC oligo as a control. The Kd value deter-
mined from this competition assay for the AAUAAA
11-mer oligo was 3.10±0.17 nM (Table 1), 10-fold higher
than the FAM-labeled 11-mer oligo. This indicates that the
FAM label enhances the binding of the 11-mer oligo.
The Kd value determined from the competition assay for
the AAUAAA 8-mer oligo was 57±18 nM (Table 1), 18-fold
higher than the 11-mer oligo in the same assay (P value
<0.001), and that for the 7-mer oligo was 35-fold higher
(Table 1). The 6-mer oligo showed some binding only at
above 2000 nM concentration (Fig. 2B), in contrast to the
good affinity for the FAM-labeled 6-mer oligo (Fig. 2A).
The FAM label in this oligo is located at the 3′ end, which
introduces a phosphate group at that position, while the
unlabeled 6-mer oligo has only a hydroxyl group at the
3′ end. Therefore, the higher affinity of the FAM-labeled
6-mer oligo is likely due to contributions from both the 3′
phosphate group and the body of the FAM. Overall, these
data indicate that nucleotides outside the AAUAAA hex-
amer, especially the phosphate group of the 7th nt, also
contribute substantially to the binding.
Variation of the U3–A6 Hoogsteen base pair
A U3–A6 Hoogsteen base pair was observed in the PAS
when bound to the CPSF-160–WDR33–CPSF-30 ternary
complex (Fig. 1C; Clerici et al. 2018; Sun et al. 2018).
The binding mode of the PAS suggests that other
Hoogsteen base pairs, such as C3–G6, could be accom-
modated, while a wobble U3–G6 base pair would not fit.
To assess whether the alternative Hoogsteen base pair
can support binding to the ternary complex, we deter-
mined the binding affinity of unlabeled 11-mer RNA with
AACAAG (variations from the AAUAAA PAS are indicated
by underlines) as the equivalent of the AAUAAA PAS by
competition fluorescence polarization assays. The experi-
mental data showed no binding of the oligo even at
5000 nM concentration (Table 1; Fig. 2C), indicating that
the alternative Hoogsteen base pair could not be accom-
modated in the binding site. The 11-mer RNA with
AAAAAU as the PAS showed no binding either.
We also characterized the binding of FAM-labeled 17-
mer RNAs with AAGAAA and AACAAA as the PAS, to
test the effect of breaking the U3–A6 Hoogsteen base
pair. These RNAs did show binding to the ternary complex,
with Kd values of 15.5 ± 1.3 and 50.3±9.2 nM, respectively
(Table 1; Fig. 2A), roughly 55- and 180-fold higher than the
17-mer AAUAAA RNA. The Kd value for the AAGAAA
oligo is consistent with that reported in an earlier study
(Clerici et al. 2017).
Variation of other positions of the AAUAAA PAS
Besides the U3–A6 Hoogsteen base pair, the structures
show that A1 and A4 of the AAUAAA PAS are specifically
recognized by CPSF-30, with hydrogen-bonds to the N1
and N6 atoms of the adenine base (Clerici et al. 2018;
Sun et al. 2018). A2 and A5 establish good hydrogen-
bonding interactions only from their N1 atoms. To assess
the binding affinity of other PAS hexamers that can also
support 3′-end processing, we selected from those hexam-
ers identified in mammalian pre-mRNAs (Beaudoing et al.
2000; Tian et al. 2005), changing each of these four posi-
tions at a time. The unlabeled 11-mer RNAs that we stud-
ied included GAUAAA (∼1% frequency, first position),
AUUAAA (∼16%, second position), AAUGAA (∼1%, fourth
position), and AAUACA (∼2%, fifth position) as the PAS.
The experimental data showed that these variant PAS
RNAs havemuch lower affinity for the ternary complex, ex-
cept for AUUAAA, which is the secondmost frequently ob-
served PAS (Fig. 2D). The Kd value for AUUAAA 11-mer
oligo is 17.2± 2.3 nM (Table 1), about sixfold higher than
the corresponding 11-mer AAUAAA oligo (P value
<0.001). TheGAUAAA11-mer oligo showed somebinding
above 2000 nM, while the AAUGAA and AAUACA 11-mer
oligos showed only minor binding at 5000 nM concentra-
tion (Fig. 2D). AAGAAA is another PAS hexamer with low
TABLE 1. Summary of observed dissociation constants
aThe dissociation constants for FAM-labeled RNAs were measured by
direct fluorescence binding assays, while those for unlabeled RNAs were
measured by competition fluorescence binding assays. Each experiment
was repeated three times, and the reported values are mean± standard
error.
bn.b., no binding observed
cThe mixture also contained CPSF-160 (full-length)–WDR33 (1–425), and
Fip1 (159–200) was coexpressed with CPSF-30. CPSF-30 was at fivefold
molar excess over CPSF-160–WDR33.
dThe mixture also contained CPSF-160 (full-length)–WDR33 (1–425), and
Fip1 (159–200) was coexpressed with CPSF-30.
Recognition of the AAUAAA polyadenylation signal
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frequency (∼3%), and it had Kd of 15.5± 1.3 nM (55-fold
higher, although the RNA carried a FAM label) (Fig. 2A).
Mutations of CPSF-30
Besides hydrogen-bonding interactions between the ade-
nine bases and the backbone of CPSF-30, there are also
extensive van der Waals interactions. Specifically, the A1,
A2, A4, and A5 bases are each involved in π-stacking inter-
action with an aromatic side chain of CPSF-30: A1 with
Phe84, A2 with His70, A4 with Phe112, and A5 with
Phe98 (Fig. 1C). In addition, A2 is flanked on the other
face by two Lys side chains, Lys77 and Lys78, and Arg73
has ionic interactions with the phosphate connecting nu-
cleotides U3 and A4.
To test the importance of these interactions for PAS RNA
binding, we produced the H70A, R73A, K77A/K78A,
F84A, and F112A mutants of CPSF-30. Each mutant and
the wild-type CPSF-30 was coexpressed with Fip1, which
produced sharp peaks on a gel filtration column
(Supplemental Fig. S1), suggesting the complex is well-
folded and monodisperse. The purified complex was
mixed with the CPSF-160–WDR33 binary complex (which
also produced a sharp peak on a gel filtration column,
Supplemental Fig. S1), with CPSF-30 at fivefold molar ex-
cess, which we showed was sufficient to achieve maximal
binding to the RNA (see next). The affinity of these mix-
tures for the FAM-labeled 17-mer RNA was then deter-
mined (Fig. 3). The K77A/K78A mutant had roughly
twofold higher Kd (0.34±0.05 nM, Table 1) compared to
wild-type CPSF-30 (P value of 0.19), which had a Kd of
FIGURE 2. Effects of variations in the RNA on PAS recognition. (A) Fluorescence polarization binding assays of the CPSF-160–WDR33–CPSF-30
ternary complex with labeled 17-mer, 11-mer, and 6-mer AAUAAAPAS RNAs, as well as labeled 17-mer RNAswith AAGAAA and AACAAA as the
PAS (nucleotides distinct fromAAUAAAare indicated by underline). The curves represent fitting to the binding data. (B) Competition fluorescence
polarization binding assays of the CPSF-160–WDR33–CPSF-30 ternary complex with unlabeled 11-mer, 8-mer, 7-mer, and 6-mer AAUAAA PAS
RNAs. Labeled 17-mer AAUAAA PAS RNAwas used as the reporter. (C ) Competition fluorescence polarization binding assays of the CPSF-160–
WDR33–CPSF-30 ternary complex with unlabeled 11-mer RNAs containing variations of the U3–A6 Hoogsteen base pair, AAAAAU, and
AACAAG. (D) Competition fluorescence polarization binding assays of the CPSF-160–WDR33–CPSF-30 ternary complex with unlabeled
11-mer RNAs containing variations of the A1, A2, A4, and A5 bases. Fip1 (159–200) is included in all the assays. Error bars are ±1 standard de-
viations from triplicate experiments.
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0.19±0.03 nM in this assay. On the other hand, the F84A
and R73Amutations had larger effects on the binding, with
eight- and 17-fold higher Kd values (P value <0.001).
Finally, the H70A and F112A mutants showed the largest
effects, with 90- and 140-fold higher Kd values (P values
<0.001).
Requirement of both WDR33 and CPSF-30
for RNA binding
The AAUAAA RNA is bound at the interface between
WDR33 and CPSF-30 (Fig. 1C), and our earlier electropho-
retic mobility shift assays showed that CPSF-30 alone, or
the CPSF-160–WDR33 and CPSF-160–CPSF-30 binary
complexes could not bind the RNA (Sun et al. 2018). To
characterize these interactions more quantitatively, we
mixed the CPSF-30–Fip1 complex at increasing molar ra-
tios (0-, 0.5-, 1-, 5-, 10-, and 20-fold) relative to the
CPSF-160–WDR33 binary complex, and observed a clear
enhancement of the apparent affinity of the mixture for
the RNA when CPSF-30 concentration was increased
(Fig. 4A). Above fivefold molar ratio of CPSF-30-Fip1 rela-
tive to CPSF-160–WDR33, maximal RNA binding was ob-
tained, with essentially the same Kd values (Table 1). In
fact, even an equal molar amount of CPSF-30–Fip1 was
sufficient to achieve nearly maximal binding, with three-
fold higher Kd (P value 0.17), indicating a high affinity of
CPSF-30 for CPSF-160–WDR33. On the other hand, in
the absence of CPSF-30, no binding was observed even
at 10 nM concentration of the CPSF-160–WDR33 binary
complex. Similarly, no RNA binding was observed for the
mixture of CPSF-160 and CPSF-30 (with Fip1) below 10
nM, and for CPSF-30–Fip1 below 200 nM concentration
(Fig. 4B), consistent with both WDR33 and CPSF-30 being
required for RNAbinding. The segment of Fip1 included in
the complex with CPSF-30 (residues 159–200) showed no
binding to this RNA (Fig. 4B).
CPSF-160 is a scaffold in the complex, recruiting both
WDR33 and CPSF-30 and positioning them correctly for
PAS RNA binding. On the other hand, the RNA directly
contacts both WDR33 and CPSF-30 (Fig. 1A), raising the
question whether WDR33 and CPSF-30 can form a com-
plex with the PAS RNA in the absence of CPSF-160. We
carried out fluorescence polarization binding assays using
purified WDR33 alone (residues 1–425, as an MBP fusion
protein), CPSF-30 (full-length) in complex with Fip1, and
their mixture. The affinity of the proteins for the RNA was
FIGURE 3. Effects of mutations in CPSF-30 on PAS recognition.
Fluorescence polarization binding assays between the labeled
17-mer AAUAAA PAS RNA andmixtures of the CPSF-160–WDR33 bi-
nary complex and CPSF-30 wild-type and mutants (coexpressed with
Fip1) at fivefoldmolar ratio. Error bars are ±1 standard deviations from
triplicate experiments.
FIGURE 4. Characterization of the roles of CPSF-160, WDR33, and
CPSF-30 in RNA binding. (A) Both CPSF-30 and WDR33 are required
for PAS RNA binding. Fluorescence polarization binding assays be-
tween the labeled 17-mer AAUAAA PAS RNA and mixtures of the
CPSF-160–WDR33 binary complex and CPSF-30 (full-length, coex-
pressed with Fip1) at increasing molar ratios. (B) WDR33 (containing
residues 1–425 as a MBP fusion protein) and CPSF-30 (full-length,
coexpressed with Fip1) cannot achieve high-affinity RNA binding in
the absence of CPSF-160. WDR33 and CPSF-30 alone also have low
affinity for the RNA. Error bars are ±1 standard deviations from tripli-
cate experiments.
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very low, with binding observed only above 10 nM concen-
tration, and we did not observe any enhanced binding of
the RNA for the mixture of WDR33 and CPSF-30 (Fig.
4B). We also carried out these experiments with ZF2–ZF3
of CPSF-30 and obtained essentially the same results
(Fig. 4B). Therefore, WDR33 and CPSF-30 cannot syner-
gistically give rise to high-affinity binding of the PAS
RNA in the absence of CPSF-160.
DISCUSSION
Overall, our studies have provided detailed knowledge
on PAS recognition by the CPSF-160–WDR33–CPSF-30
ternary complex. They extend beyond the earlier fluores-
cence polarization experiments (Clerici et al. 2017), by
characterizing the binding affinity of additional PAS hex-
amers, the importance of the Hoogsteen base pair, the
effect of RNA length, the effects of mutating CPSF-30
residues in the binding site. These studies also extend
beyond our gel shift experiments (Sun et al. 2018) on
these interactions, by examining additional complexes
and by providing quantitative measures of the binding
affinity.
Our results confirm that both hydrogen-bonding and
van der Waals interactions are important for the recogni-
tion of the A1, A2, A4, and A5 bases. Changing the iden-
tity of these bases generally has strong deleterious effects
on the binding affinity, with the exception of the AUUAAA
sequence, consistent with it also being frequently ob-
served for 3′-end processing. On the other hand, loss of
π-stacking interactions with these bases is also detrimental
for the recognition. The structure suggests that the U2
base of AUUAAA could maintain the hydrogen-bond
with the main-chain amide of Lys78 in CPSF-30 with a
small conformational change, as well as the π-stacking
with His70 (Fig. 1C).
Our studies demonstrate the importance of the U3–A6
Hoogsteen base pair for high-affinity binding to the terna-
ry complex. The AAAAAU hexamer, swapping the posi-
tions of the U3 and A6 nucleotides, cannot maintain a
Hoogsteen base pair as the AAUAAA hexamer (Supple-
mental Fig. S2), explaining the lack of binding for this
RNA. On the other hand, the AACAAG hexamer appears
to fit nicely into the binding site (Supplemental Fig. S2),
with the guanine base flanked on either side by Phe43
and Phe153 of WDR33 and picking up a hydrogen-bond
between its 2-amino group and the main-chain carbonyl
of Thr115 in WDR33. The exact reason why this hexamer
cannot bind with high affinity is not clear, although it is
consistent with the fact that it is not frequently observed
for 3′-end processing (Tian et al. 2005). At the same
time, the AAGAAA and AACAAA hexamers are able to
bind the ternary complex, albeit with substantially reduced
affinity, indicating that a base pair here may not be abso-
lutely required for binding.
The less frequently observed PAS motifs studied here
appear to have a much lower affinity for the ternary com-
plex. The AAUAAA hexamer is most often associated
with the last PAS in human and mouse pre-mRNAs, while
the less frequently observed hexamers are associated
with upstream PAS of pre-mRNAs with two or more pro-
cessing sites (Tian et al. 2005). Especially, the AAGAAA
hexamer is often found as the PAS in an upstream exon.
This suggests that these less frequently observed PAS hex-
amers have a more prominent role in alternative polyade-
nylation. A possible mechanism is that other protein
factors (such as CstF) as well as recognition of auxiliary se-
quence motifs may have a larger contribution to the bind-
ing of the pre-mRNA, thereby facilitating processing at
these sites.
MATERIALS AND METHODS
Protein expression and purification
A human CPSF-160–WDR33 (residues 1–425) binary complex was
expressed in baculovirus-infected Hi5 insect cells as described
earlier (Sun et al. 2018). WDR33 carried an amino-terminal His-
tag followed by MBP and a TEV protease cleavage site. Full-
length human CPSF-30 was cloned into ampicillin-resistant
pET15_NESG, with amino-terminal His and SUMO tags. Human
Fip1 (residues 159–200) was cloned into the pET28a vector
(Novagen), also with amino-terminal His and SUMO tags. The
proteins were expressed in E. coli BL21(DE3) cells. Coexpression
with the Fip1 fragment helped to prevent aggregation of CPSF-
30. The components were mixed together for the binding assays,
allowing the variation of the molar ratios of CPSF-30 relative to
CPSF-160–WDR33.
A CPSF-160–WDR33–CPSF-30 ternary complex was expressed
in Hi5 insect cells with the Multibac expression system (Sari et al.
2016) (Geneva Biotech). WDR33 (residues 1–425) carried an
amino-terminal His-tag, followed by MBP and a TEV protease
cleavage site. CPSF-160 and CPSF-30 were untagged.
The CPSF-160–WDR33–CPSF-30 and the CPSF-160–WDR33
complexes were purified following the same protocol. The insect
cells were lysed by sonication in a buffer containing 50 mM Tris
(pH 8.0), 500 mM NaCl, 30 mM imidazole, 10 mM β-mercaptoe-
thanol, and one SIGMAFAST protease inhibitor cocktail tablet.
The lysate was mixed with 2 mL Ni-NTA beads (Qiagen), washed
with 15 mL buffer containing 2 M NaCl to remove bound nucleic
acids, then the protein was eluted with 5 mL buffer containing
250 mM imidazole. One milligram TEV protease was added,
and the sample was incubated overnight at 4°C. It was then run
over a Superdex200 16/60 column (GE Healthcare), using a buffer
containing 20 mM (Tris 8.0), 350 mM NaCl, and 10 mM DTT.
For Fip1, the cells were lysed by sonication in a buffer contain-
ing 50 mM Tris (pH 8.0), 200 mMNaCl, 30 mM imidazole, 10 mM
β-mercaptoethanol, and 2 mM PMSF. The lysate was incubated
with 5 mL Ni-NTA, washed with 30 mL buffer, then Fip1 was elut-
ed with 10 mL buffer containing 250 mM imidazole and 100 mM
NaCl. To remove the His-SUMO tag, 100 µg UlpI protease was
added, and the sample was incubated at 4°C overnight. It was
then purified further using a 5 mL Fastflow MonoQ column
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followed by a Superdex200 16/60 column using a buffer contain-
ing 20 mM Tris (pH 8.0), 100 mM NaCl, and 10 mM DTT.
The cells coexpressing Fip1 and CPSF-30 were lysed by sonica-
tion in a buffer containing 50 mM Tris (pH 7.5), 500 mM NaCl,
30 mM imidazole, 10 mM β-mercaptoethanol, 100 µM ZnSO4,
and 2 mM PMSF. The lysate was incubated with 5 mL Ni-NTA,
washed with 20 mL buffer containing 2 M NaCl, then eluted
with 10 mL buffer containing 250 mM imidazole, 100 µM
ZnSO4, and 500 mM NaCl. To remove the His-SUMO tag,
100 µg UlpI protease was added, and the sample was incubated
at 4°C overnight. It was then incubated again with 5mLNi-NTA to
remove the His-tagged SUMO, and the flow-through was run over
a Superdex 200 16/60 column using a buffer containing 20 mM
Tris (pH 7.5), 500 mM NaCl, 100 µM ZnSO4, and 10 mM DTT.
The excess Fip1 was removed by this gel filtration step.
Fluorescence polarization binding assays
The assays were performed at room temperature using a Neo2S
plate reader (Biotek). The buffer for all the assays contained
20 mM Tris (pH 8.0), 150 mM NaCl, 10 mM DTT, 0.01% (v/v)
NP-40, and 100 nM BSA. Oligonucleotides that included a poly-
adenylation site and the surrounding bases from the SV40 virus
and a 6-carboxyfluorescein (6-FAM) label at the 5′ or 3′ end
were used in direct binding assays. Oligonucleotides without a
FAM label were used in competition binding assays. A 17-mer ol-
igonucleotide with a 5′-end FAM label was used as the probe at a
concentrationof 1 nM in theseexperiments, and theproteinwas at
25 nM. For assays that involved titrationwith CPSF-30, variousmo-
lar ratios of CPSF-30 (in complex with Fip1) were added to CPSF-
160–WDR33. For other binding assays, 1 µM Fip1 was also includ-
ed. All the mixtures were incubated on ice for 1 h and then trans-
ferred to 384-well plates at room temperature. Oligonucleotides
were purchased from IDT. All titration experiments were carried
out in triplicate.
Both the direct and competition binding experimentswere fit to
analytical equations (Wang 1995; Lundblad et al. 1996) using the
optimize package from SciPy version 1.1.0 (Oliphant 2007). The fit
to direct binding data took into account the depletion of the free
probe during the titration. Statistical significance was tested by
performing an F-test using both the global fit and individual fits
of pairs of curves, with the stats package from SciPy version 1.1.0.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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Fig. S1. Gel filtration profiles during the purification of CPSF-30–Fip1 complex (left) and CPSF-160–WDR33 
complex (right). The shaded area represents fractions that were pooled for the purified sample. Based on 
molecular weight standards, the apparent molecular weight of the CPSF-30–Fip1 complex is 49 kDa (44 kDa 









Fig. S2. A C3-G6 Hoogsteen base pair (magenta) appears to be accommodated the same way as the U3-A6 Hoogsteen 
base pair (orange). On the other hand, replacing U3 and A6 with A3 and U6 leads to serious steric clashes between 
the bases (gold, line drawings), which could be relieved if the adenine adopts a syn configuration, but would not 










Molecular mechanism for the interaction
between human CPSF30 and hFip1
Keith Hamilton and Liang Tong
Department of Biological Sciences, Columbia University, New York, New York 10027, USA
Most eukaryotic pre-mRNAs must undergo 3′-end cleavage and polyadenylation prior to their export from the nu-
cleus. A large number of proteins in several complexes participate in this 3′-end processing, including cleavage and
polyadenylation specificity factor (CPSF) in mammals. The CPSF30 subunit contains five CCCH zinc fingers (ZFs),
with ZF2–ZF3 being required for the recognition of theAAUAAApoly(A) signal. ZF4–ZF5 recruits the hFip1 subunit
of CPSF, although the details of this interaction have not been characterized. Here we report the crystal structure of
humanCPSF30 ZF4–ZF5 in complex with residues 161–200 of hFip1 at 1.9 Å resolution, illuminating themolecular
basis for their interaction. Unexpectedly, the structure reveals one hFip1 molecule binding to each ZF4 and ZF5,
with a conserved mode of interaction. Our mutagenesis studies confirm that the CPSF30–hFip1 complex has 1:2
stoichiometry in vitro. Mutation of each binding site in CPSF30 still allows one copy of hFip1 to bind, while mu-
tation of both sites abrogates binding. Our fluorescence polarization binding assays show that ZF4 has higher affinity
for hFip1, with a Kd of 1.8 nM. We also demonstrate that two copies of the catalytic module of poly(A) polymerase
(PAP) are recruited by the CPSF30–hFip1 complex in vitro, and both hFip1 binding sites in CPSF30 can support
polyadenylation.
[Keywords: cleavage and polyadenylation; pre-mRNA 3′-end processing; zinc finger]
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In eukaryotes, most mRNA precursors (pre-mRNAs) are
cleaved and polyadenylated at their 3′ end prior to their ex-
port from the nucleus (Zhao et al. 1999; Shi and Manley
2015; Sun et al. 2020a). This sequence of events is careful-
ly orchestrated, with multiple protein complexes binding
to different cis elements in the pre-mRNA, providing both
a tight regulation of cleavage/polyadenylation and the op-
portunity to select from multiple cleavage sites with var-
ious affinities (alternative polyadenylation [APA]) (Tian
and Manley 2017; Gruber and Zavolan 2019). Switching
between these sites can lead to changes in the length
and sequence of the 3′ UTR of mRNAs, which has many
effects in protein expression, mRNA stability, and locali-
zation (Mayr 2017).
In mammals, a large number of proteins in several
complexes contribute to the selection of cleavage and pol-
yadenylation sites. These include cleavage and polyade-
nylation specificity factor (CPSF), cleavage stimulation
factor (CstF), mammalian cleavage factor I (CFIm), CFIIm,
and poly(A) polymerase (PAP), which adds the poly(A) tail.
CPSF consists of two subcomplexes:mammalian polyade-
nylation specificity factor (mPSF) that recognizes the con-
served polyadenylation signal (AAUAAA) upstream of the
cleavage site and recruits PAP, and mammalian cleavage
factor (mCF) that carries out the cleavage reaction (Chan
et al. 2014; Schönemann et al. 2014). mPSF contains
four proteins: CPSF160, WDR33, CPSF30, and hFip1,
and structures of mPSF bound to AAUAAA RNA demon-
strate that CPSF160 serves as a scaffold onto which the
N-terminal regions of WDR33 and CPSF30 are organized
to bind the RNA (Clerici et al. 2018; Sun et al. 2018).
TheC-terminal region of CPSF30 and hFip1 are not visible
in these structures, presumably because they are not in a
fixed conformation relative to the mPSF core. mCF con-
tains CPSF73, CPSF100, and symplekin, and its structure
is highly dynamic (Zhang et al. 2020) although it becomes
ordered in the active state (Sun et al. 2020b).
CPSF30 has five CCCH zinc fingers (ZF1–ZF5) near the
N terminus and a CCHC zinc knuckle near the C termi-
nus, separated by a nonconserved and putatively disor-
dered region (Fig. 1A). ZF1 is crucial for the interaction
with CPSF160, and ZF2–ZF3 recognize the AAUAAA
poly(A) signal (Clerici et al. 2018; Sun et al. 2018). ZF5
of the yeast CPSF30 homolog Yth1 is required for binding
to Fip1 (Barabino et al. 1997, 2000), which in turn tethers
PAP (Meinke et al. 2008). hFip1 may also participate in
cleavage site selection by binding to U-rich regions in
the pre-mRNA through its C-terminal arginine-rich re-
gion (Kaufmann et al. 2004), and by bridging the CFIm
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andCPSF complexes by interactingwith the RS domain of
CFIm68 or CFIm59 through its own RS domain (Zhu et al.
2018). These two interactions contribute to the selection
of polyadenylation sites, making hFip1 an important reg-
ulator of APA.
It has previously been observed that CPSF30 interacts
with residues 137–243 of hFip1 (Kaufmann et al. 2004), al-
though the details of this interaction have not been char-
acterized. Here we report the crystal structure of human
CPSF30 ZF4–ZF5 in complex with residues 161–200 of
hFip1 at 1.9 Å resolution, illuminating the molecular
basis for their interaction. Unexpectedly, the structure re-
veals one hFip1 molecule binding to each ZF4 and ZF5,
with a conserved mode of interaction. Our fluorescence
polarization binding assays show that ZF4 has higher af-
finity for hFip1, with a Kd of 1.8 nM.We also demonstrate
that two copies of the catalytic module of PAP (Bard et al.
2000; Martin et al. 2000) are recruited by the CPSF30–
hFip1 complex in vitro.
Results
Overall structure of CPSF30–hFip1 complex
To obtain a more precise definition of the region of hFip1
that interacts with human CPSF30, we coexpressed ZF2–
ZF5 of CPSF30 (residues 62–173) together with progres-
sively shorter versions of hFip1 starting from residues
137–243 (Kaufmann et al. 2004), and assessed complex for-
mation by gel filtration chromatography. The shortest ver-
sion of hFip1 that could interact with CPSF30 contained
residues 159–200, which we then used for crystallization.
Small crystals were observed from the initial crystalli-
zation screening using a sample containing ZF2–ZF5 of
human CPSF30 (residues 62–173) and hFip1 (residues
159–200). However, these crystals took 2 mo to appear
and could not be reproduced. We noticed that there were
molds growing in the crystallization solution, and our ear-
lier observations suggest that a protease secreted by the
molds may have cleaved the protein(s), which was re-
quired for crystallization (Mandel et al. 2006; Bai et al.
2007b). We then introduced trypsin into the protein solu-
tion, which greatly improved the crystallization and pro-
duced crystals within a few days. We screened through
various constructs for CPSF30 and hFip1, and the best
crystals were obtained using a sample containing ZF4–
ZF5 of CPSF30 (residues 114–173) coexpressed with
hFip1 (residues 159–200), with trypsin at 1:280 weight ra-
tio. The structure was determined at 1.9 Å resolution (Ta-
ble 1) using the anomalous signal from the zinc atoms.
The electron density for one of the two hFip1molecules






Figure 1. Structure of the humanCPSF30–hFip1 complex. (A) Domain organizations of humanCPSF30 and hFip1. The five zinc fingers of
CPSF30 are shown in green,withZF4 andZF5 in a brighter color. The zinc knuckle of CPSF30 is shown in gray. The segments of hFip1 that
interact with CPSF30 and PAP are shown in yellow and gray, respectively. (B) Schematic drawing of the structure of the human CPSF30–
hFip1 complex. CPSF30 is in green. The hFip1 molecule bound to ZF4 is in yellow, and that bound to ZF5 is in brown. (C ) Overlay of the
ZF4–hFip1 complex (in color) and the ZF5–hFip1 complex (gray). Residue 191 at the C-terminal end of the hFip1 bound to ZF5 is labeled.
(D) Sequence alignment of theCPSF30 zinc fingers. The ligands of the zinc ions are in pink, and residues in ZF4 and ZF5 that contribute to
hFip1 binding are in red. Residues in ZF2 and ZF3 that contact the A-A dinucleotide are in orange, and residues whose main chain hydro-
gen bonds to the dinucleotide are underlined. (E) Overlay of the zinc fingers of CPSF30 and their binding partners. ZF1 is in magenta, ZF2
in blue and ZF4 in green. TheA-A dinucleotide bound to ZF2 is shown in orange. ZF3 and ZF5 are not shown for clarity, as their structures
are similar to that of ZF2 and ZF4, respectively. Structure figures are produced with PyMOL (www.pymol.org).
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involved in crystal packing, and additional C-terminal res-
idues would not be compatible with the crystal packing.
In addition, the first residue observed for CPSF30 is
Ile121, while residue 120 is Lys. Ile121 is also involved
in crystal packing, and additional N-terminal residues
here would not be compatible with the crystal packing ei-
ther. In fact, Ile121 is located near Lys191 of the truncated
hFip1molecule in another asymmetric unit of the crystal.
Therefore, in situ proteolysis by trypsin (or a fungal prote-
ase) of both CPSF30 and hFip1 was essential for this
crystallization.
Both ZF4 and ZF5 of CPSF30 are well ordered in the
structure, and the C-terminal extension beyond ZF5 (res-
idues 169–173) is positioned between the two zinc fingers,
helping to stabilize the structure (Fig. 1B). To our surprise,
we observed twomolecules of hFip1 in complexwith each
CPSF30molecule in the structure, one primarily bound to
ZF4 (hFip1-A) and the other to ZF5 (hFip1-B). Residues
162–200 are observed for hFip1-A, while residues 161–
191 are observed for hFip1-B. This segment of hFip1 con-
tains a loop (residues 161–181) followed by a long helix
(residues 182–198). Residues at the N terminus (161–
170) of this segment have weaker electron density as
they do not have many contacts with CPSF30.
The conformations of the two zinc fingers are highly
similar to each other (Fig. 1C), with an RMS distance of
0.54 Å for 23 equivalent Cα atoms between them, consis-
tent with the high sequence conservation between them
(Fig. 1D). Moreover, the binding modes of the two hFip1
molecules are similar to each other as well (Fig. 1C). An
overlay of the ZF4–hFip1-A and ZF5–hFip1-B structures
produces an RMS distance of 0.52 Å for 53 equivalent
Cα atoms. The C-terminal helix of the two hFip1 mole-
cules are located in the same position, even though that
of hFip1-B is shorter because of the proteolysis (Fig. 1C).
The similarity in the two complexes also indicate that
crystal packing, especially for residue Lys191 in hFip1-B,
has essentially no impact on the interactions between
CPSF30 and hFip1.
The structures of the five zinc fingers of CPSF30 are
similar to each other in general (Fig. 1E). However, they
use different surfaces for interacting with their binding
partners. ZF2 and ZF3 use one face of the zinc finger to
bind A-A dinucleotides with the same binding mode
(Sun et al. 2018) and to bind the NS1 protein of influenza
virus (Das et al. 2008). ZF1 uses the same face to bind the
N-terminal extension of CPSF30 (Clerici et al. 2018; Sun
et al. 2018) with the side chain of Gln22 being located at
the same position as the first base of the A-A dinucleotide.
In contrast, ZF4 and ZF5 use the opposite face of the zinc
finger to bind hFip1. Residues Pro125 in ZF4 and Pro157
in ZF5 would abolish the hydrogen-bonding interactions
observed between the main chain of the equivalent resi-
dues in ZF2 and ZF3 and A-A dinucleotide (Fig. 1D). In
fact, the Pro residues would also cause steric clash with
the base of the nucleotides. Therefore, ZF4 and ZF5 are
unlikely to bind RNA with high affinity.
Binding mode of hFip1 in CPSF30
Residues 173–188 of hFip1, in the loop prior to the helix
and the first two turns of the helix, have extensive interac-
tions with the zinc finger of CPSF30. For the interface be-
tween ZF4 and hFip1-A, 750 Å2 of the surface area of each
protein is buried here. The His142 ligand to the zinc ion is
hydrogen-bonded to the main chain carbonyl of Asp174
(in hFip1-A), while the side chain of Asp174 has ionic in-
teractions with that of Arg144 (ZF4) (Fig. 2A). The side
chain hydroxyl of Tyr127 (ZF4) is hydrogen-bonded to
the main chain carbonyl of Ser173 (hFip1-A), and its phe-
nyl ring is sandwiched between the side chains of His142
(ZF4) and Asn177 (hFip1-A). The side chain of Phe131
(ZF4) is part of a cluster of aromatic residues from hFip1-
A. This residue is conserved in ZF5, but not the other
three zinc fingers of CPSF30 (Fig. 1D). Generally, residues
in the CPSF30–hFip1 interface are highly conserved
among their homologs (Fig. 2B,C).
For the interface between ZF5 and hFip1-B, 480 Å2 of
the surface area of each protein is buried here. Residues
His142, Arg144, Tyr127, and Phe131 of ZF4 are conserved
as His166, Arg168, Tyr151, and Phe155 in ZF5, and these
residues maintain essentially the same interactions with
hFip1-B (Fig. 2D). The main chain of Arg168 is placed
against Arg129 in ZF4 and assumes a different
Table 1. Summary of crystallographic information




a, b, c (Å) 79.0, 79.0, 48.7
α, β, γ (°) 90, 90, 120
Resolution (Å)a 48.7–1.9 (1.94–1.90)
Rmerge (%) 4.6 (87.4)
CC1/2 1.000 (0.788)
I/σI 30.9 (3.1)
Completeness (%) 100.0 (99.9)
No. of reflections 13793 (869)
Redundancy 12.6 (10.9)
Refinement
Resolution (Å) 39.6–1.9 (1.95–1.90)
Rwork (%) 17.9 (26.2)
Rfree (%) 20.9 (24.9)









Bond lengths (Å) 0.017





aThe numbers in parentheses are for the highest-resolution
shell.
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conformation compared with Arg144, but the guanidi-
nium groups of the two Arg residues are located at the
same position. The smaller buried surface area in this in-
terface is because hFip1-A also has some contacts with
ZF5 and the C-terminal extension beyond it, especially
residue Phe169, which is part of the aromatic residue clus-
ter in ZF4 (Fig. 2A).
There are also contacts between the C-terminal helix of
hFip1-A and the loop of hFip1-B (Fig. 1B), giving rise to 300
Å2 buried surface area in this interface. However, the
bound conformations of the two hFip1 molecules are
nearly the same (Fig. 2D), and therefore it is unlikely
that these contacts have affected the binding modes of
hFip1.
Mutation studies confirm two hFip1-binding sites in
CPSF30
To assess the structural observations on the CPSF30–
hFip1 interface, especially the 1:2 stoichiometry of the
two proteins in the complex, we introduced mutations
in the binding site and characterized their effects on the
complex. We mutated Tyr127 in ZF4 and the equivalent
Tyr151 in ZF5 to Ala, either separately or together.
We first characterized the complexes by gel filtration
studies. We used the ZF2 C terminus construct of
CPSF30 (residues 62–244, 21 kDa), as this protein alone
has higher solubility and is more stable in solution (the
ZF4–ZF5 protein alone has very low solubility; it can
only be produced when coexpressed with hFip1). This re-
combinant protein is a monomer in solution by gel filtra-
tion, with an apparent molecular weight of 23 kDa (Fig.
3A). When mixed with threefold molar excess of hFip1
(residues 159–200, 5 kDa, corresponding to the segment
that interacts with CPSF30 in the structure), wild-type
CPSF30 produced a complex with an apparent molecular
weight of 34 kDa, suggesting the presence of two copies
of hFip1 and one CPSF30 molecule. By comparison, the
Y127A and the Y151A mutants could only associate
with one copy of hFip1 (29 kDa), while the Y127A/
Y151A double mutant lost the ability to form a complex
with hFip1 (23 kDa). These observations demonstrate
the important role of Tyr127 and Tyr151 in the interac-
tions with hFip1, and confirm that the CPSF30–hFip1
complex has 1:2 stoichiometry in vitro.
ZF4 has higher affinity for hFip1 than ZF5
We next used fluorescence anisotropy studies to deter-
mine the affinity between CPSF30 and hFip1. We used a
hFip1 protein that contained residues 159–200. We creat-
ed the S159C/C189S mutant to introduce a cysteine resi-
due outside of the interface with CPSF30, and labeled this
protein with FAM. The CPSF30 sample contained resi-
dues 62–244, from ZF2 to the C terminus. The Kd for
the complex of wild-type CPSF30 and hFip1 was 0.69 ±
0.31 nM (Fig. 3B), indicating a strong interaction between
the two proteins. TheKd for the Y151Amutant of CPSF30
was 1.8 ± 0.4 nM, while that for the Y127A mutant was
220± 32 nM. Finally, no binding was observed for the
Y127A/Y151A double mutant at 1.5 μM concentration.
These data indicate that ZF4 has high affinity for hFip1,




D Figure 2. Detailed interactions between
human CPSF30 and hFip1. (A) Interactions
between ZF4 (green) and hFip1 (yellow).
Side chains in the interface are shown as
stick models. Hydrogen-bonding interac-
tions are shown as dashed lines (red). Resi-
due Tyr127 is labeled in red. (B) Sequence
alignment of ZF4–ZF5 of CPSF30 homo-
logs. Residues contributing >50 Å2 buried
surface area in the complex with hFip1 in
ZF4 are highlighted in blue, and those in
the complexwith hFip1 in ZF5 are in green.
(Hs) Homo sapiens, (Mm) Mus musculus,
(Xt) Xenopus tropicalis, (Dr) Danio rerio,
(Dm) Drosophila melanogaster, (Sc) Sac-
charomyces cerevisiae. (C ) Sequence align-
ment of hFip1 homologs in the segment
that interact with CPSF30. (D) Interactions
between ZF5 (green) and hFip1 (brown),
overlaid with the ZF4–hFip1 complex
(gray). Residue Tyr151 is labeled in red.
Panels B andC aremodified from an output
from ESPript (Gouet et al. 1999).
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consistent with the smaller buried surface area in this
complex.
We also used a longer hFip1 sample that contained res-
idues 137–243, with the S159C/C189S/C216S mutation
to allow labeling with FAM. The Kd values for wild-type
and Y151A mutant CPSF30 were 11.4 ± 4.9 nM and 5.4 ±
1.0 nM, respectively (Fig. 3B). By comparison, the Kd val-
ues for theY127Amutantwas 22± 6 nM,while no binding
was observed for the Y127A/Y151A double mutant at 1.5
μM concentration. These data suggest that longer hFip1
may enhance binding to ZF5.
The CPSF30–hFip1 complex can recruit two PAP
molecules
The segment of yeast Fip1 that tethers PAP (Meinke et al.
2008) is weakly conserved in hFip1, located N-terminal to
the segment that interacts with CPSF30 (Fig. 1A). The 1:2
stoichiometry of the CPSF30–hFip1 complex suggests
that it could recruit two copies of PAP. We purified the
catalytic module (residues 1–524, 60 kDa) of human
PAPα (Martin et al. 2000) and studied its mixture with
CPSF30 and hFip1 by gel filtration. The hFip1 sample
used in these studies contained residues 79–200
(13 kDa), to include the region that recruits PAP. The
CPSF30 sample used in these studies was full-length (res-
idues 1–244, 27 kDa). The hFip1 protein containing the re-
gion that recruits PAP is a dimer in solution, which
produced a 2:4 complex of CPSF30–hFip1, while the
Y127A and Y151A mutants reduced the complex to 2:2
(Fig. 3C). PAP alone is a monomer in solution (Fig. 3C).
In the mixture of PAP catalytic module with wild-type
CPSF30 and hFip1, a complex with an apparentmolecular
weight of 161kDawasobserved (Fig. 3C), consistentwith a
1:2:2 complex of CPSF30–hFip1–PAP (173 kDa). By com-
parison, the Y127A or Y151A mutant of CPSF30 formed
a complex with an apparent molecular weight of 101
kDa, consistentwith a1:1:1 complex (100kDa). Therefore,
these studies confirm that theCPSF30–hFip1 complex can
recruit twomolecules of the catalyticmodule of PAP in vi-
tro. They also suggest that the hFip1 dimer dissociated
upon formation of the complex with the PAP catalytic
A C
B
Figure 3. Biochemical and biophysical characterizations of the human CPSF30–hFip1 complex. (A) Gel filtration profiles for the mix-
tures of CPSF30 and hFip1 for wild-type CPSF30, Y127A mutant, Y151A mutant, and Y127A/Y151A double mutant. CPSF30 contained
residues ZF2-C terminus (62–244), and hFip1 contained residues 159–200. The peak for excess hFip1 is indicated. (B) Fluorescence polar-
ization binding assays for the CPSF30–hFip1 complex. hFip1 residues 159–200 (S159C/C189S mutant, red) and 137–234 (S159C/C189S/
C216S mutant, blue) was labeled with FAM, and titrated with increasing concentrations of CPSF30 (residues 62–244). Error bars are ±1
standard deviation from triplicate experiments. (C ) Gel filtration profiles for mixtures of CPSF30 (full-length), hFip1 (residues 79–200),
and the catalytic module of PAP (residues 1–524). The maximum absorbance is arbitrarily scaled to 1. Gel filtration profiles for mixtures
of CPSF30 (full-length) and hFip1 (residues 79–200) are also shown, with the maximum absorbance scaled to 0.5.
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module, probably because the region that mediates this
dimerization is also the region that interacts with PAP.
The Y127A/Y151A double mutant of full-length CPSF30
has poor behavior in solution and could not be purified
for this experiment, likely because it cannot interact
with hFip1.
We next tested the ability of wild-type and mutant
CPSF30 proteins to support polyadenylation.We observed
clear polyadenylation activity with full-length wild-type
CPSF30 as well as the Y127A and the Y151A mutants us-
ing an RNA containing the AAUAAA poly(A) signal (Fig.
4). In contrast, no polyadenylation activity was observed
in a reaction lacking CPSF30 or using an RNA containing
the AAGAAA poly(A) signal (Fig. 4). Nonspecific polyade-
nylation was observed in reactions lacking CPSF30 and
hFip1 but containing Mn2+ as the divalent cation. These
results suggest that both hFip1 binding sites in CPSF30
can support polyadenylation.
Discussion
Overall, our studies have revealed the molecular basis for
the recruitment of hFip1 by CPSF30. The residues in the
interface are highly conserved among CPSF30 (Fig. 2B)
and hFip1 (Fig. 2C) homologs, from yeast to humans, indi-
cating that this binding mode is likely conserved in most
organisms. In addition, hFip1 is mostly an unstructured
protein, with few conserved segments. The segment that
interacts with CPSF30 is the most conserved region
among its homologs, especially for fungal Fip1.
Combined with the earlier study on the recognition of
the AAUAAA poly(A) signal (Clerici et al. 2018; Sun
et al. 2018), we have now defined the molecular basis for
the functions of each of the five zinc fingers in CPSF30.
The overall structures of the zinc fingers are similar, in
the shape of a short, oval cylinder. The zinc atom and its
three Cys ligands are located near one end of this cylinder
(the “bottom” face). This bottom face is used by ZF2 and
ZF3 to recognize anA-A dinucleotide and by ZF1 to recog-
nize a segment of CPSF30 itself (Fig. 1E). In contrast, ZF4
and ZF5 use the “top” face of this cylinder, where the His
ligand to the zinc ion is located, to bind hFip1. Therefore,
different side chains of the zinc fingers participate in bind-
ing the partners (Fig. 1D), depending on whether they are
pointed toward the top or bottom face.
Residue Lys191 of hFip1 is in a helix, but it is a cleavage
site for trypsin in hFip1-B. A helical conformation for this
residue would not be able to access the active site of tryp-
sin, indicating that residues in this region can undergo
conformational changes between a helical conformation
and a more extended conformation. Trypsin can cleave
at this residue when it is in the extended conformation.
Two Kd values would be expected from the fluorescence
anisotropy studies on wild-type CPSF30 binding to hFip1,
because ZF4 and ZF5 appear to have different inherent
affinity for hFip1. However, there is no evidence for this
in the binding curve. It could be possible that the interac-
tions between the two hFip1molecules in the complex en-
hance the affinity of hFip1 for ZF5, so that the two zinc
fingers have comparable apparent affinity for hFip1. The to-
tal buried surface area for hFip1-B in this complex is 770Å2,
which is more comparable with that for hFip1-A, 1070 Å2.
TheCPSF30–hFip1 complexprovides a linkbetween the
recognitionof theAAUAAApoly(A) signal and the recruit-
ment of PAP to the machinery. Unexpectedly, our studies
revealed a 1:2 stoichiometry betweenCPSF30 andhFip1 in
this complex in vitro, although ZF4 has higher affinity for
hFip1. It remains tobeestablishedwhether this stoichiom-
etry is also true in the active 3′-end processing machinery
in vivo. Recent mass spectrometry studies have found up
to two copies of Fip1 and Pap1 in the yeast machinery
(Casanal et al. 2017). Several other factors in theprocessing
machinery are dimeric, such as CstF77 (Bai et al. 2007a;
Legrand et al. 2007; Paulson and Tong 2012), CstF50 (Mo-
reno-Morcillo et al. 2011), and especially the CFIm25-
CFIm68 complex (Yang et al. 2011). CFIm recognizes the
UGUA sequence element (Hu et al. 2005; Venkataraman
et al. 2005;Yanget al. 2010),which is enrichednear thedis-
tal cleavage site (Wang et al. 2018; Zhu et al. 2018). There-
fore, CFIm plays an important role in APA. At the same
time, CFIm also interacts with PAP (Dettwiler et al.
2004) and hFip1 (Venkataraman et al. 2005), and therefore
a dimeric CFIm in the complex may be compatible with
having two copies of hFip1 and PAP.
Materials and methods
Protein expression and purification
Human CPSF30 was cloned into a pET28a vector modified to be
ampicillin resistant, either with no affinity tag (residues 114–
Figure 4. Both hFip1-binding sites in CPSF30 support polyade-
nylation. The RNA primer contained the AAUAAAor AAGAAA
poly(A) signal, with a FAM label at the 5′ end. Full-length wild-
type, Y127A, and Y151A mutants of CPSF30 (100 nM) together
with hFip1 (100 nM) and CPSF160-WDR33 (50 nM) showed poly-
adenylation activity with the AAUAAA RNA, while a reaction
lacking CPSF30 showed no activity. Nonspecific polyadenyation
was observed in the presence of 1 mM Mn2+ as the divalent cat-
ion. The reactions were carried out in triplicate, and only one rep-
licate is shown. The other two replicates produced essentially the
same results.
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173), or with an N-terminal His-tagged yeast SMT3 (residues 62–
244 or 1–244). We used isoform 2 of CPSF30, where residues 191–
215 are missing. With this isoform, full-length CPSF30 has 244
residues. hFip1 (residues 159–200 or 79–200) and human PAPα
(residues 1–524) were each cloned into a pET28a vector, in-frame
withN-terminalHis-tagged yeast SMT3 as a solubility tag.Muta-
tions to CPSF30 and hFip1 were carried out using the Quik-
Change protocol (Agilent).
All expressions were carried out in LBmedia using E. coli BL21
(DE3) cells. Each was induced with 0.5 mM IPTG and incubated
for 18 h at 17°C prior to harvesting by centrifugation. The result-
ing cell pellets were flash-frozen and stored at −80°C until use.
CPSF30, hFip1, PAPα, and CPSF30–hFip1 complexes were all
purified using the same protocol, except that in samples contain-
ing CPSF30, 100 μM ZnSO4 was added to all buffers, and those
with full-length CPSF30 had at least 500 mM NaCl at all times.
First, the cells were lysed using sonication in buffer containing
50 mM Tris (pH 7.5), 200 mM NaCl, 30 mM imidazole, 10 mM
β-mercaptoethanol, and 2 mM PMSF. The lysate was centrifuged
to clarify and the supernatant incubated with 5 mL Ni-NTA
beads (Qiagen) at 4°C. The beads were then washed with two col-
umn volumes of buffer containing 2.5 M NaCl, then three col-
umn volumes with 100 mM NaCl, and finally eluted with
buffer containing 100 mM NaCl and 250 mM imidazole. One-
hundred micrograms of UlpI protease was added to the elution
and allowed to cleave overnight at 4°C. After cleavage, the sample
was run over a 5-mL Fast Flow HiPrep Q column (GE Healthcare)
using a 100 mM to 2 M NaCl gradient. Fractions were analyzed
using SDS-PAGE, and the appropriate ones were purified further
using a Superdex 200 16/60 column (GEHealthcare) with a buffer
containing 20mMTris (pH 7.5), 100mMNaCl, and 10mMDTT.
CPSF30 alonewas purified in the samemanner as above, butwith
50mMarginine and at least 500mMNaCl in the buffer during all
steps, and a secondNi-NTApurification postcleavage and prior to
MonoQ purification.
Human CPSF160/WDR33 (residues 1–425) complex was ex-
pressed and purified using a previously described protocol (Sun
et al. 2018; Hamilton et al. 2019).
Protein crystallization
Crystals of the human CPSF30 (residues 114–173) and hFip1 (res-
idues 159–200) complex were obtained with 14 mg/mL protein
using the sitting-drop vapor-diffusion method at 20°C. Trypsin
(50 μg/mL) was added to the protein sample prior to setup, and
the reservoir solution contained 0.1 M sodium malonate (pH
5.7) and 16% (w/v) PEG 3350. Crystals appeared overnight, and
were picked after 2mo and flash-frozenwith liquid nitrogen using
30% (v/v) glycerol as the cryo-protectant.
Data collection and structure determination
X-ray diffraction data were collected at the NE-CAT 24-ID-C
beamline at the Advanced Photon Source. The diffraction images
were processed using XDS (Kabsch 2010), and the phases were
solved using the CRANK2 pipeline (Skubák and Pannu 2013)
in the CCP4 suite (Collaborative Computational Project, Num-
ber 4 1994) using the anomalous scattering of the zinc atoms.
The structure was rebuilt using Coot (Emsley and Cowtan
2004) and refined with Refmac5 (Murshudov et al. 1997). The
atomic structure and X-ray diffraction data have been deposited
in the Protein Data Bank (entry code 7K95).
Labeling of hFip1 with FAM
hFip1 (100 μM; residues 159–200 or 137-234) mutated to only
have one cysteine that was outside of the CPSF30 binding region
(S159C/C189S or S159C/C189S/C216S) was mixed with 2 mM
fluorescein-5-maleimide (Cayman Chemical Company) in a buff-
er consisting of 20 mM Tris (pH 7.5), 100 mM NaCl, and 1 mM
TCEP. The reaction was allowed to proceed overnight at 4°C in
darkness. The next day, unreacted maleimide was rendered inac-
tive by the addition of 10 mM DTT. The fluorescein-labeled
hFip1 was then purified using a Superose 12 10/300 column (GE
Healthcare).
Fluorescence polarization binding assays
Fluorescence polarization assays were performed on a Synergy
Neo2 plate reader (Biotek) with polarizing filters (485 ± 20 nm ex-
citation, 528±20-nm emission). The buffer contained 20 mM
Tris (pH 7.5), 200 mM NaCl, 1 mM DTT, 0.03% NP-40, 0.1 μM
BSA, and 5 nM FAM-labeled hFip1 for wild-type CPSF30 and
10 nM labeled hFip1 for the CPSF30 mutants. Each titration
was carried out in triplicate, and the results were analyzed using
a locally developed Python program.
Analytical gel filtration experiments
Fifty microliters of each sample was mixed and incubated for 1 h
on ice and then run on a Superose 12 10/300 column (GE Health-
care). The buffer contained 20 mM Tris (pH 7.5), 200 mM NaCl,
and 10 mM DTT. The molecular weight of the eluted samples
was calculated using a linear equation calibratedwith a set of pro-
tein standards (Bio-Rad).
Polyadenylation assays
Assayswere carried out following amodified version of a protocol
detailed previously (Wahle 1995). All reactionswere carried out in
triplicate in a volume of 7.5 μL using a buffer that consisted of
20 mM Tris (pH 8.0), 10% (v/v) glycerol, 150 mM NaCl, 5 mM
MgCl2, 10 μMEDTA, 0.03% (v/v)NP-40, 10mMDTT, 1 unit/reac-
tion RNasin Plus RNase inhibitor (Promega), 1 μM BSA (Sigma),
and 1 μM PABPN1 (residues 45–296). The AAUAAA RNA primer
is from the human adenovirus L3 polyadenylation site, with the
sequence UUCAAUAAAGGCAAAUGUUUUUAUUUGUACA.
The reactions were heated at 30°C for 5 min prior to addition of
1mMATP (Sigma), then allowed to react for 10min at 30°C prior
to stopping with the addition of 7.5 μL 2× stop buffer (40mMTris
at pH 8.0, 8M urea, 100mMEDTA) and heating for 10min to 65°
C. The reactions were separated by running them on an 8% (w/v)
acrylamide urea gel in TBE buffer, and then visualized using a Ty-
phon FLA 7000 (GE Healthcare).
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